

NOVEL GARDNERELLA ENDOLYSINS AND USES THEREOF

[0001] The present invention relates to new species-selective phage endolysins and their use to treat bacterial vaginosis (BV). The present invention provides recombinant endolysins, *i.e.* domain-swapped endolysins. The invention also relates to said endolysins for use in treating diseases or disorders such as bacterial infections, in particular BV. The invention further relates to polynucleotides encoding said endolysins. Said polynucleotides can also be used for treating such diseases or disorders. Also provided by the present invention is a pharmaceutical composition comprising an endolysin of the invention for use in treating such diseases or disorders. Said endolysins, polynucleotides and pharmaceutical composition may be administered locally, in particular locally into the vagina.

[0002] Bacterial vaginosis (BV), also been referred to in the literature as bacterial vaginitis, non-specific vaginosis and non-specific vaginitis, is the most common vaginal infection worldwide and is associated with significant adverse consequences including preterm labor and delivery, post-partum endometritis and an increased risk of HIV acquisition. It is a dysbiosis of the vagina where the commensal *Lactobacilli* are displaced by a polymicrobial biofilm, the pH increases from the natural 3.5-4.5 up to 5.5, and a malodorous fluid forms. Reported prevalence rates range from 10-40% depending upon the population studied. However, suboptimal methods of diagnosis and a high percentage of asymptomatic patients make the true prevalence of BV difficult to ascertain. *Gardnerella vaginalis* (*G. vaginalis*) is a bacterial species associated with BV.

[0003] The etiopathogenesis of BV remains poorly understood. It is most commonly defined as a pathological state characterized by the loss of normal vagina flora, particularly of H₂O₂-producing species of *Lactobacillus*, and the simultaneous overgrowth of anaerobic bacteria including *G. vaginalis*, *Mobiluncus* species, and *Mycoplasma hominis*. Recent data however, suggest a primary role for *G. vaginalis* as a specific and sexually transmitted etiological agent in BV (Muzny et al., 2016, J. of Infect. Dis. 214 Suppl. 1., S1).

[0004] In the 1950s, abundant small, pleomorphic gram-variable rods were observed in the genital tract of women with BV. This organism, first called *Haemophilus vaginalis* and repeatedly renamed as more information about its characteristics became available, is now classified as *G. vaginalis* which, until 2018, was considered to be the sole member of the genus

Gardnerella. However in early 2019 it was shown that the genus *Gardnerella* actually contains at least 13 species, and the most frequent ones were renamed *G. vaginalis sensu stricto*, *G. leopoldii*, *G. piovii*, and *G. swidsinskii* (Vaneechoutte et al., 2019 Int. J. Syst. Evol. Biol. 898661).

[0005] Bacteria of the genus *Gardnerella* are special in that they are Gram-variable, i.e. they do not form the outer membrane defining the Gram-negative species. The cell wall is generally very thin and has only 10% or less content of peptidoglycan, which is why the crystal violet dye used for Gram staining does not always yield the deep purple color typical for Gram-positive species. Rather, *Gardnerella* cells can appear both Gram positive and negative in a Gram staining. Phylogenetic analysis based on 16S rRNA places *Gardnerella* in the gram-positive family *Bifidobacteriales*.

[0006] During BV, the epithelial surface is covered with a dense collection of *G. vaginalis* in a biofilm that is frequently recalcitrant to treatment. Biofilms are adherent communities of microorganisms held together by a polymeric matrix composed of polysaccharides, proteins and/or nucleic acids. The distinct gene expression pattern, as well as the physical structure of biofilms increases bacterial resistance to many negative stimuli including chemical disinfectants, pH extremes, host immune defenses and antibiotics. Standard of BV treatment are the antibiotics Metronidazole and Clindamycin, which however often fail to eradicate the biofilm, so that recurrence rates are up to 60% within 6 months. Furthermore, treatment with antibiotics wipes the vaginal microbiome, despite leaving some rests of viable biofilm, which opens this ecological niche for other pathogens, e.g. fungi. A frequent effect of BV treatments is therefore candidosis. Treatment of BV was also attempted with probiotics, specifically with beneficial *Lactobacilli* supposed to re-colonize the vagina. However, several clinical trials failed to show a benefit.

[0007] Therefore, there is a great need for new methods and compositions to treat *G. vaginalis* infections and particularly BV, e.g. by selectively killing bacterial cells of the genus *Gardnerella*, preferably without harming the beneficial *Lactobacilli* while they re-populate the vagina. Thus, the technical problem underlying the present invention is the provision of novel means and methods for the treatment of BV.

The technical problem is solved by provision of the embodiments characterized in the claims.

[0008] The present invention is based on the preparation of novel recombinant *Gardnerella* prophage endolysins with unexpected properties and structure which make them particularly suitable for various uses and methods, in particular for treating, decontaminating or detecting, bacterial infections and disorders, in particular in relation with *Gardnerella*.

[0009] A first aspect of the invention provides an endolysin comprising or consisting of

(i) a N-terminal catalytic domain, or a functional variant thereof;

(ii) a C-terminal cell-wall binding region, or a functional variant thereof, wherein the C-terminal cell-wall binding region comprises or consists of at least one cell-wall binding domain; and

(iii) a linker region between the N-terminal catalytic domain and the C-terminal cell-wall binding region,

wherein the endolysin has a killing activity against *Gardnerella*.

[0010] In one aspect of the invention the N-terminal catalytic domain is from a first natural endolysin, the linker region and the C-terminal cell-wall binding region are from a second natural endolysin, and the first and the second natural endolysins are encoded by different genomes from different prophages. Thus, the invention provides a recombinant endolysin comprising or consisting of

(i) a N-terminal catalytic domain, or a functional variant thereof;

(ii) a C-terminal cell-wall binding region, or a functional variant thereof, wherein the C-terminal cell-wall binding region comprises or consists of at least one cell-wall binding domain; and

(iii) a linker region between the N-terminal catalytic domain and the C-terminal cell-wall binding region,

wherein the N-terminal catalytic domain is from a first natural endolysin, the linker region and the C-terminal cell-wall binding region are from a second natural endolysin, and the first and the second natural endolysins are encoded by different genomes from different prophages, and

wherein said recombinant endolysin has a killing activity against *Gardnerella*.

[0011] *Gardnerella* is special in that it is a Gram-variable species: it does not form the outer membrane defining true Gram-negative species. Its cell wall is generally very thin and has only 10% or less content of peptidoglycan. This indicates that a peptidoglycan-degrading enzyme, such as endolysin proteins, could not efficiently lyse the bacterial cell walls of *Gardnerella*. However, in the context of the present invention novel recombinant endolysins have been identified which have the advantageous property that they effectively kill *Gardnerella* species, and thus, could be used as a novel therapy for the treatment of BV.

[0012] The healthy vagina is populated mainly by 3 species of *Lactobacilli*: *L. crispatus*, *L. gasseri* and *L. jensenii*. These maintain an acidic pH of 3.5-4.5, by producing lactic acid, and a protective oxidative milieu, by producing H₂O₂. Recovery from BV is associated with a re-population of the vagina with these *Lactobacilli*. However, antibiotics (which are conventionally used for the treatment of BV) have the disadvantages that they interfere with the process of re-population of the vagina with *Lactobacilli*. In contrast, the novel recombinant endolysins of the invention advantageously have a species-selective killing activity against *Gardnerella* and do not harm *Lactobacilli*. In addition, the appended Examples show that all tested *Gardnerella* strains have a low susceptibility to Metronidazole and Clindamycin, which are conventionally used in the treatment of BV. This could explain the high recurrence rates of BV. This also sustains that the endolysins of the invention are superior to antibiotics in the treatment of BV. Accordingly, treating BV with the endolysins of the invention is far advantageous to the currently available treatments, such as the treatments with the antibiotics Metronidazole and Clindamycin.

[0013] Herein the term “from a first natural endolysin” means that the respective part (*i.e.* the N-terminal catalytic domain) is identical to or a functional variant of a first natural endolysin. As defined herein, a functional variant is a polypeptide which has at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of the respective part (*i.e.* the N-terminal catalytic domain) of a first natural endolysin and results in a functional endolysin, wherein the function comprises killing activity against *Gardnerella*. The amino acid sequences of several natural endolysins are provided herein below and are summarized in Table 7.

[0014] In line with this term “from a second natural endolysin” means that the respective part (*i.e.* the linker region and C-terminal cell-wall binding region) is identical to or a functional variant of a second natural endolysin, *i.e.* an endolysin which is different from the first natural endolysin. As defined herein, a functional variant is a polypeptide which has at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of the respective part (*i.e.* the

linker region and C-terminal cell-wall binding region) of the second natural endolysin and results in a functional endolysin, wherein the function comprises killing activity against *Gardnerella*.

[0015] Herein, the N-terminal catalytic domain is also referred to as “H-domain”. For example, the term “H2” refers to the H-domain of the natural endolysin (EL) 2. The “C-terminal cell-wall binding region” refers to one or more cell-wall binding domains. The linker and the cell-wall binding domains represent together the so-called “B-region”. For example, B10 refers to the B-region of the natural EL10. Likewise, B11_N refers to the N-terminal cell-wall binding domain of natural EL11, B12_C refers to the C-terminal cell-wall binding domain of natural EL12 and so on.

[0016] The invention further provides an endolysin comprising or consisting of

(i) a N-terminal catalytic domain consisting of a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 1 to 5, 7, or 10 to 12, or any functional variant thereof having at least 80% identity with the amino acid sequence of any one of SEQ ID NOs: 1 to 5, 7, or 10 to 12;

(ii) a C-terminal cell-wall binding region comprising or consisting of at least one cell-wall binding domain independently selected from the group consisting of polypeptides comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 15 to 24 and 26 to 33, respectively, and any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of any one of SEQ ID NOs: 15 to 24 and 26 to 33, respectively; and

(iii) a linker region between the N-terminal catalytic domain and the C-terminal cell-wall binding region,

wherein said endolysin has a killing activity against *Gardnerella*.

[0017] As shown in the appended Examples, the most active N-terminal catalytic domain (also referred to as “H-domain”) is H2 (SEQ ID NO: 2), followed by H7 (SEQ ID NO: 7), H10 (SEQ ID NO: 10) and H5 (SEQ ID NO: 5).

[0018] Thus, in a preferred aspect of the present invention the N-terminal catalytic domain is consisting of a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 2, 7, 10 and 5, or any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more

preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of any one of SEQ ID NOs: 2, 7, 10 and 5;

whereby the endolysin is functional, wherein the function comprises the ability to lyse the cell wall of *Gardnerella*.

[0019] Accordingly, in a preferred aspect of the present invention the N-terminal catalytic domain is consisting of a polypeptide which comprises or consists of the amino acid sequence of SEQ ID NO: 5, or any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 5; or more preferably comprising or consisting of the amino acid sequence of SEQ ID NO: 10, or any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 10; or even more preferably comprising or consisting of the amino acid sequence of SEQ ID NO: 7, or any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 7; or even more preferably comprising or consisting of the amino acid sequence of SEQ ID NO: 2, or any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 2;

whereby the endolysin is functional, wherein the function comprises the ability to lyse the cell wall of *Gardnerella*.

[0020] It is also shown in the appended Examples that of the B-regions B10 (comprising the cell-wall binding domains of SEQ ID NOs: 28 and 29) is the most active, followed by B11 (comprising the cell-wall binding domains of SEQ ID NOs: 30 and 31), B12 (comprising the cell-wall binding domains of SEQ ID NOs: 32 and 33), and B3 (comprising the cell-wall binding domains of SEQ ID NOs: 19 and 20).

[0021] Thus, in a preferred aspect of the present invention the cell-wall binding domain(s) of is/are selected from the group consisting of polypeptides comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 19, 20 and 28-33, and any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of any one of SEQ ID NOs: 19, 20 and 28-33;

whereby the endolysin is functional, wherein the function comprises the ability to lyse the cell wall of *Gardnerella*.

[0022] The endolysin of the present invention comprises preferably two cell-wall binding domains. In one aspect of the present invention the cell-wall binding domains (B-domains) of the endolysin of the invention consists of a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 19, 20 and 28-33, and any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of any one of SEQ ID NOs: 19, 20 and 28-33;

whereby the endolysin is functional, wherein the function comprises the ability to lyse the cell wall of *Gardnerella*.

In a preferred aspect of the present invention the endolysin comprises a first cell-wall binding domain and a second cell-wall binding domain, wherein said first cell-wall binding domain is selected from the group consisting of SEQ ID NOs: 15, 17, 19, 21, 23, 26, 28, 30 and 32, and said second cell-wall binding domain is selected from the group consisting of SEQ ID

NOs: 16, 18, 20, 22, 24, 27, 29, 31 and 33. Preferably, said first cell-wall binding domain is N-terminally of said second cell-wall binding domain.

[0023] In a more preferred aspect of the present invention the endolysin comprises the two cell-wall binding domains (B-domains) of natural endolysin EL10 (SEQ ID NOs: 28 and 29), of natural endolysin EL11 (SEQ ID NOs: 30 and 31), of natural endolysin EL12 (SEQ ID NOs: 32 and 33), or of natural endolysin EL3 (SEQ ID NOs: 19 and 20), even more preferably of natural endolysin EL10 (SEQ ID NOs: 28 and 29); or a functional variant thereof. Said functional variant may also be a set of two B-domains having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequences of the two B-domains of natural endolysin EL10 (SEQ ID NOs: 28 and 29), of natural endolysin EL11 (SEQ ID NOs: 30 and 31), of natural endolysin EL12 (SEQ ID NOs: 32 and 33), or of natural endolysin EL3 (SEQ ID NOs: 19 and 20), even more preferably of natural endolysin EL10 (SEQ ID NOs: 28 and 29);

whereby the endolysin is functional, wherein the function comprises the ability to lyse the cell wall of *Gardnerella*.

[0024] In one aspect of the present invention the cell-wall binding domain(s) (B-domain(s)) comprise(s) or consist(s) of the amino acid sequence of SEQ ID NO: 19 and/or 20, or any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 19 and/or 20; more preferably comprises or consists of the amino acid sequence of SEQ ID NO: 32 and/or 33, or any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 32 and/or 33; even more preferably comprises or consists of the amino acid sequence of SEQ ID NO: 30 and/or 31, or any functional variant thereof having at least 80% identity (preferably at least 85%

identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 30 and/or 31; or even more preferably comprises or consists of the amino acid sequence of SEQ ID NO: 28 and/or 29, or any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 28 and/or 29;

whereby the endolysin is functional, wherein the function comprises the ability to lyse the cell wall of *Gardnerella*.

[0025] It is preferred that the sequence VNELL or VNKLL, more preferably VNELL, is located at the C-terminus of the B-domain. In case of the presence of a plurality of B-domains within the B-region, it is also preferred that the sequence VNELL or VNKLL, more preferably VNELL, is located at the C-terminus of each B-domain. **[0026]** Surprisingly and unexpectedly, it has been found in the context of the present invention that several recombinant endolysins have a stronger activity than natural endolysins, especially when viewed across all 4 *Gardnerella* strains tested (*i.e.* *Gardnerella vaginalis sensu strict*, *Gardnerella leopoldii*, *Gardnerella piovii* and *Gardnerella swidsinskii*). Particularly H2B10, H2B11, H2B12 and H7B3 are each more active than all tested natural endolysins. Thus, recombinant endolysins according to the present invention exhibit significantly higher activity than the natural endolysins.

[0027] Therefore, it is preferred that the “killing activity against *Gardnerella*” of the recombinant endolysin of the invention is enhanced as compared to the killing activity of natural endolysins, e.g. natural endolysins EL1-EL12 (having the amino acid sequences as shown in Table 7).

[0028] In line with the considerably high activity of endolysins H2B10, H2B11, H2B12, and H7B3, these endolysins (and their functional variants) are preferred in the present invention. Thus, the endolysin of the present invention has preferably:

(i) a N-terminal catalytic domain consisting of a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2 or 7, or any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more

preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 2;

(ii) a C-terminal cell-wall binding region comprising or consisting of at least one (preferably two) cell-wall binding domain(s) independently selected from the group consisting of polypeptides comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 19, 20 and 28 to 33, respectively, and any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 19, 20 and 28 to 33, respectively; and

(iii) a linker region between the N-terminal catalytic domain and the C-terminal cell-wall binding region consisting of a polypeptide comprising or consisting of the amino acid sequence $X_1X_2GLNGX_3X_4NGGS$, wherein X_1 is N or K, preferably N, X_2 is A, X_3 is Y and X_4 is K or Q,

wherein said endolysin has a killing activity against *Gardnerella*. Regarding the linker region it is indicated that, as mentioned below, the linker region may also consist of a polypeptide comprising or consisting of the amino acid sequence $(XXX)_n$, wherein each X can be independently G, A or S, preferably wherein the amino acid sequence $(XXX)_n$ is $(GGS)_n$, wherein n corresponds to the number of repetitions of the sequence XXX, preferably wherein n is 2, 3, 4, 5 or 6.

[0029] In the appended Examples the recombinant endolysin H2B10 was shown to have the highest activity. Therefore, it is most preferred in the present invention that the endolysin of the present invention is H2B10 (or a functional variant thereof). Accordingly, the endolysin of the present invention has most preferably:

(i) a N-terminal catalytic domain consisting of a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2, or any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence SEQ ID NO: 2;

(ii) a C-terminal cell-wall binding region comprising or consisting of two cell-wall binding domains consisting of polypeptides comprising or consisting of the amino acid sequence

of SEQ ID NO: 28 or 29, or any functional variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NO: 28 or 29; and

(iii) a linker region between the N-terminal catalytic domain and the C-terminal cell-wall binding region consisting of a polypeptide comprising or consisting of the amino acid sequence $X_1X_2GLNGX_3X_4NGGS$, wherein X_1 is N, X_2 is A, X_3 is Y and X_4 is K,

wherein said endolysin has a killing activity against *Gardnerella*. As mentioned above, it is preferred that the “killing activity against *Gardnerella*” of the recombinant endolysin of the invention is enhanced as compared to the killing activity of natural endolysins, e.g. natural endolysins EL1-EL12 (having the amino acid sequences as shown in Table 7).

Regarding the linker region it is indicated that, as mentioned below, the linker region may also consist of a polypeptide comprising or consisting of the amino acid sequence $(XXX)_n$, wherein each X can be independently G, A or S, preferably wherein the amino acid sequence $(XXX)_n$ is $(GGS)_n$, wherein n corresponds to the number of repetitions of the sequence XXX, preferably wherein n is 2, 3, 4, 5 or 6.

[0030] In the recombinant endolysin of the present invention the C-terminal cell-wall binding region may comprise or consists of one, two or three cell-wall binding domains. Said one, two or three cell-wall binding domains may be independently selected from the group consisting of the polypeptides comprising or consisting of the amino acid sequence of SEQ ID NOs: 15 to 24 and 26 to 33, respectively, and any variants thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NOs: 15 to 24 and 26 to 33, respectively, whereby said polypeptides are functional, wherein the function comprises the ability to bind to the cell wall of *Gardnerella*. It is preferred that the C-terminal cell-wall binding region consists of two cell-wall binding domains. Preferred C-terminal cell-wall binding regions are defined herein above and below.

[0031] The endolysin of the present invention does preferably not comprise the H-domain or B-region of natural endolysin EL6. The amino acid sequences of the H-domain and B-region of natural endolysin EL6 are shown in Table 7.

[0032] The linker region may consist of a polypeptide having a length of 6 to 18 amino acids, preferably a length of 9 to 15 amino acids, even more preferably a length of 12 amino acids. Preferably, the linker region may consist of a polypeptide comprising or consisting of the amino acid sequence (i) (XXX)_n, wherein each X can be independently G, A or S, preferably wherein the amino acid sequence (XXX)_n is (GGS)_n, wherein n corresponds to the number of repetitions of the sequence XXX, preferably wherein n is 2, 3, 4, 5 or 6, or (ii) X₁X₂GLNGX₃X₄NGGS, wherein X₁ is N or K, X₂ is A or V, X₃ is Y or C and X₄ is K or Q. As described above, in one aspect of the endolysin of the present invention the N-terminal catalytic domain is identical to or derived from a first natural endolysin, the linker region and the C-terminal cell-wall binding region are identical to or derived from a second natural endolysin, and the first and the second natural endolysins are encoded by different genomes from different prophages.

[0033] The recombinant endolysin of the present invention has killing activity against *Gardnerella*. For example, the endolysin of the present invention may have killing activity against *Gardnerella vaginalis sensu stricto*, *Gardnerella leopoldii*, *Gardnerella piotii* and/or *Gardnerella swidsinskii*, preferably against all of them. The killing activity of the endolysins of the invention as described above against *Gardnerella* is preferably a genus-selective killing activity against *Gardnerella*. Herein “genus-selective killing activity against *Gardnerella*” means that the endolysin of the present invention does not have killing activity against bacteria in general. Preferably, the endolysin of the present invention has killing activity against *Gardnerella*, but not against *Lactobacilli*. In particular, it is preferred that said endolysin has no killing activity against *Lactobacilli crispatus*, *Lactobacilli gasseri*, and/or *Lactobacilli jensenii*. More preferably, said endolysin has no killing activity against all of these *Lactobacilli*, i.e. *Lactobacilli crispatus*, *Lactobacilli gasseri*, and *Lactobacilli jensenii*.

[0034] The invention also relates to a polynucleotide molecule encoding an endolysin as described above. The nucleic acid molecule may be DNA, e.g. cDNA, or RNA. Herein, the terms “polynucleotide” or “polynucleotide molecule” is used synonymously with the term “nucleic acid molecule” or the like.

[0035] The invention also relates to a vector comprising said polynucleotide molecule of the invention. In one embodiment, the vector is an expression vector. Any suitable vector known in the art may be used, such as the pET series of vectors and all the T7 based vectors. For

example, the vector may be a plasmid. Thus, one aspect of the present invention relates to a plasmid comprising the polynucleotide of the invention. It will be appreciated by persons skilled in the art that the choice of expression vector may be determined by the choice of the host cell.

[0036] Also provided by the present invention is a host cell comprising the polynucleotide molecule according to the invention or the vector/plasmid according to the invention. In one embodiment, the host cell is a microbial cell, for example a bacterial cell. Preferably the host cell is non-pathogenic. Most preferably the host cell is *E. coli*. Thus, one aspect of the invention relates to a bacterial host cell comprising the plasmid of the invention, preferably wherein the bacterial host cell is an *E. coli* cell.

[0037] Also encompassed by the present invention is a method for producing the endolysin of the invention comprising culturing a population of host cells comprising the polynucleotide molecule according to the invention or a vector/plasmid according to the invention under conditions in which the endolysin is expressed, and isolating the endolysin therefrom.

[0038] A further aspect of the invention provides a pharmaceutical composition comprising

- (a) an endolysin according to the invention;
 - (b) a polynucleotide molecule according to the invention;
 - (c) a vector/plasmid according to the invention;
 - (d) a host according to the invention; and/or
 - (e) a bacteriophage capable of expressing an endolysin according to the invention
- and a pharmaceutically acceptable carrier, diluent or excipient. For example, the pharmaceutical composition of the present invention may comprise the endolysin of the invention, the polynucleotide molecule of the invention, and a pharmaceutically acceptable carrier and/or diluent.

[0039] A further aspect of the invention relates to

- (a) an endolysin according to the invention;
- (b) a polynucleotide molecule according to the invention;
- (c) a vector/plasmid according to the invention;
- (d) a host according to the invention;
- (e) a bacteriophage capable of expressing an endolysin according to the invention; and/or
- (f) a pharmaceutical composition according to the invention

for use in treating a disease or disorder. For example, the invention provides an endolysin according to the invention, a polynucleotide molecule according to the invention, or a

pharmaceutical composition according to the invention for use in treating a disease or disorder. Said disease or disorder may be a bacterial infection, preferably bacterial vaginosis. For example, the bacterial vaginosis may be caused by *Gardnerella vaginalis sensu strict*, *Gardnerella leopoldii*, *Gardnerella piovai* and/or *Gardnerella swidsinskii*.

[0040] In one aspect of the present invention the recombinant endolysin of the invention, the polynucleotide molecule of the invention, or the pharmaceutical composition of the invention is to be administered locally, preferably locally into the vagina of a subject. Thus, in one aspect of the present invention the recombinant endolysin of the invention, the polynucleotide of the invention, or the pharmaceutical composition of the invention is to be administered into the vagina of a subject.

[0041] The appended Examples show that the activity of the recombinant endolysins of the present invention is particularly high at a pH around pH 5. Therefore, one aspect of the present invention relates to the recombinant endolysin of the invention, the polynucleotide molecule of the invention, or the pharmaceutical composition of the invention, wherein said recombinant endolysin, polynucleotide or pharmaceutical composition is to be co-administered with a compound or composition which adjusts the pH of the vagina to 4.0 – 6.0, preferably to 4.5-5.5, more preferably to about 5. Suitable compounds or compositions which adjust the pH of the vagina include but are not limited to phosphate, lactic acid (e.g. the natural acidification substance which *Lactobacilli* secrete to establish an acidic milieu) or other organic acids, e.g. carboxy-substituted polymers.

[0042] A further aspect of the invention relates to

- (a) an endolysin of the invention;
 - (b) a polynucleotide molecule of the invention;
 - (c) a vector/plasmid of the invention;
 - (d) a host of the invention;
 - (e) a bacteriophage capable of expressing an endolysin of the invention; and/or
 - (f) a pharmaceutical composition of the invention
- for use as a medicament.

[0043] A further aspect of the invention concerns the use of

- (a) an endolysin of the invention;
- (b) a polynucleotide molecule of the invention;
- (c) a vector/plasmid of the invention;
- (d) a host of the invention;
- (e) a bacteriophage capable of expressing a polypeptide of the invention; and/or

(f) a pharmaceutical composition of the invention
in the manufacture of a medicament for treating bacterial infections and disorders.

[0044] A further aspect of the invention provides a method for treating bacterial infections and disorders such as BV comprising administering a subject in need thereof, a therapeutically effective amount of

- (a) an endolysin of the invention;
- (b) a polynucleotide molecule of the invention;
- (c) a vector/plasmid of the invention;
- (d) a host of the invention;
- (e) a bacteriophage capable of expressing a polypeptide of the invention; and/or
- (f) a pharmaceutical composition of the invention.

In some embodiment, the therapeutically effective amount is a dose of 10 to 100ug of endolysin, optionally to be administered several times per day.

[0045] A further aspect of the invention provides a kit comprising an endolysin as described herein and instructions of use, in particular for treating a disease or disorder, preferably BV as defined above. Said kit may also comprise a compound or composition which adjusts the pH of the vagina to 4.0 – 6.0, preferably to 4.5-5.5, more preferably to about 5. The definitions and preferred aspects defined herein above and below for the endolysin of the present invention apply, *mutatis mutandis* also for the polynucleotide molecule, vector/plasmid, host cell, pharmaceutical composition, method of treatment and kit of the present invention.

A further aspect of the invention provides an *in vitro* method for the diagnosis of a disease or condition which can be treated with the endolysin according to the present invention, the method comprising the steps of:

- (i) contacting a sample obtained from the subject with a polypeptide comprising or consisting of the C-terminal cell-wall binding region of the endolysin according to the present invention, and optionally the N-terminal catalytic domain of the endolysin according to the present invention, wherein the sample comprises microbial cells, and wherein the C-terminal cell-wall binding region of said endolysin is optionally labelled;
- (ii) testing whether the polypeptide binds to, and/or lyses, the microbial cells of the sample; and
- (iii) determining that a disease or condition can be treated with the endolysin according to the present invention if the polypeptide binds to, and/or lyses, the microbial cells.

The microbial cells may be *Gardnerella* cells, preferably cells of *G. vaginalis sensu stricto*, *G. leopoldii*, *G. piovii*, *G. swidsinskii* or other species of the genus *Gardnerella*.

Other features and advantages of the invention will be apparent from the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0046] FIG. 1 shows a sequence alignment of the natural *Gardnerella* prophage endolysins of the present disclosure (CLUSTAL O(1.2.4) multiple sequence alignment). The majority of the endolysins has 306 residues, except two which have 251 residues.

[0047] FIG. 2 shows a phylogenetic tree of the natural *Gardnerella* prophage endolysins of the present disclosure. There are no identical pairs among the endolysins, even though they are highly homologous.

[0048] FIG. 3 shows a domain structure of the *Gardnerella* prophage endolysins of the present disclosure as determined with InterPro (Mitchell *et al.*, 2019, Nucleic Acids Res. 47, D351–D360). The N-terminal part of 196 residues of the endolysins is identified as the catalytic domain, due to its homology to Glycoside hydrolases, family 25. The catalytic domain is followed by a linker region and two domains which are identified as two cell-binding domains, due to their homology to the C-terminal domain of lysozyme Cpl-7 (CW_7 domain). According to the nomenclature of the present application, the catalytic domain represents the hydrolase or “H-domain”, while the linker region and the cell-wall binding domains represent together the binding or “B-region”.

[0049] FIGS. 4A to 4C show three enzymatic activity assays where the enzymatic activity of natural *Gardnerella* prophage endolysins of the present disclosure is measured by detecting the change in turbidity of a suspension of *Gardnerella* cells. In Fig 4A, the enzymatic activity of the endolysins is measured by detecting the change in turbidity of a suspension of the *G. leopoldii* strain Gv_10 at pH 6.0. In FIG. 4B, the enzymatic activity of the endolysins is measured by detecting the change in turbidity of a suspension of the *G. piovii* strain Gv_17 at pH 7.0. In FIG. 4C, the enzymatic activity of the endolysins is measured by detecting the change in turbidity of a suspension of the *G. swidsinskii* strain Gv_23 at pH 7.4. Treatment was conducted in a medium adjusted to the appropriate pH in a photometric cuvette against buffer. Then, the change in turbidity was assessed by measuring the optical density (OD) at 600nm. As a result, the drop in turbidity was more pronounced for the endolysin treated groups than for the buffer, indicating enzymatic activity.

[0050] FIG. 5 shows a quantitative reduction in viable Colony Forming Units (CFU) assay comparing untreated cells from the *G. vaginalis sensu stricto* strain Gv_9 incubated in medium with or without imidazole at different pH values. 5×10^7 CFU/ml cells were incubated

under the conditions indicated below the graph for 5 hours at 37°C under anaerobic conditions, after which the surviving CFU/ml was determined by quantitative plating. The results show that the survival of *G. vaginalis* Gv_9 is highly dependent on the absence of imidazole and on a low pH under the tested conditions.

[0051] FIG. 6 shows a quantitative reduction in viable Colony Forming Units (CFU) assay comparing cells from the *G. vaginalis sensu stricto* strain Gv_9 treated with an eluate solution containing recombinant endolysins H10B1 and 250mM imidazole at different pH values or with a control containing 250mM imidazole at different pH values. 5×10^7 CFU/ml cells were incubated under the conditions indicated below the graph for 5 hours at 37°C under anaerobic conditions, after which the surviving CFU/ml was determined by quantitative plating. The columns labeled imidazole control depict the same data as in Fig. 5. The results show that the enzymatic activity of H10B1, as an example for all the endolysins of the invention, is higher at low pH values, with pH 5.5 and pH 5.0 showing the strongest activity.

[0052] FIGs. 7A to 7D show four quantitative reduction in viable Colony Forming Units (CFU) assays measuring the killing activity of natural and recombinant *Gardnerella* prophage endolysins of the present disclosure against the four main species of *Gardnerella*. In Fig 7A, 7B, 7C and 7D, the killing activity of the endolysins is measured by detecting the viable CFU of suspensions of the *G. vaginalis sensu stricto* strain Gv_9, the *G. leopoldii* strain Gv_11, the *G. piovii* strain Gv_17, and the *G. swidsinskii* strain Gv_23, respectively. 90ul 5×10^7 CFU/ml of the indicated strain were incubated for 5 hours at pH 5.0 under anaerobic conditions with 10ul endolysin solution (concentration adjusted to 0.2mg/ml where possible, see Table 4). The logarithmic Y axis depicts the count of surviving cells. The dotted line indicates the limit of detection (LOD) given by plating of 2ul of the reaction mix (500 CFU/ml). The results show that the endolysins of the present invention have the capacity to lyse the four main species of *Gardnerella*. The results also point out that some of the recombinant endolysins of the invention have a higher killing activity than the natural endolysins of the invention.

[0053] FIG. 8 shows a phylogenetic relationship tree (amino acid level) of H-domains created with Clustal Omega (Sievers et al., 2011 Mol. Syst. Biol. 7, 539).

[0054] FIG. 9 and FIG. 10 shows a phylogenetic relationship tree (amino acid level) of B-regions created with Clustal Omega (Sievers et al., 2011 Mol. Syst. Biol. 7, 539).

[0055] FIG. 11 shows a sequence alignment of the cell-wall binding domains (also called B-domains) within the B-region of the natural endolysins of the invention with Clustal Omega (Sievers et al., 2011 Mol. Syst. Biol. 7, 539). For each B-region, the N-terminal cell-wall binding domain is denoted with a _N suffix (Bx_N) and the C-terminal cell-wall binding domain

is denoted with a _C suffix (Bx_C). By way of example, B3_C designates the second (C-terminal) B-domains of B3.

[0056] FIG. 12 shows a phylogenetic relationship tree of the individual B-domains with Clustal Omega (Sievers *et al.*, 2011 Mol. Syst. Biol. 7, 539).

[0057] FIG. 13 shows three quantitative reduction in viable Colony Forming Units (CFU) assays measuring the killing activity of recombinant *Gardnerella* prophage endolysins of the present disclosure against the three most frequent species of beneficial *Lactobacilli*, at pH 5.0 under anaerobic conditions. The results show that the endolysins of the invention are ineffective against the beneficial *Lactobacilli* strains.

[0058] FIG. 14 shows MIC microbroth dilution activity assays measuring the effect of Metronidazole and Clindamycin (obtained from Ratiopharm as a solution for injection, 300 mg/2 ml), on the growth in suspension of the four main species of *Gardnerella*. *Gardnerella* suspensions at 2.5×10^7 CFU/ml were incubated with the concentration of antibiotics as indicated on the x-axis of each graph and incubated for 48h at 37°C under anaerobic conditions. Cell growth was evaluated by Optical Density measurement at 610nm (OD(610)) before and after incubation to determine the Minimum Inhibitory Concentration (MIC). The results show that all *Gardnerella* strains are resistant both to Metronidazole and Clindamycin (obtained from Ratiopharm as a solution for injection, 300 mg/2 ml) exhibiting MICs of 64 to <128µg/ml and 16µg/ml, respectively (FIG. 14).

FIG. 15 shows MIC microbroth dilution activity assays measuring the effect of Metronidazole and Clindamycin hydrochloride (obtained from Sigma Aldrich), on *Gardnerella* suspensions at 1×10^5 - 1×10^6 CFU/ml. This time the results show that Metronidazole had a MIC on all tested *Gardnerella* strains between 8 and 128µg/ml and Clindamycin hydrochloride powder (obtained from Sigma Aldrich (C5269-10MG)) exhibited MICs between 0.25 and 5µg/ml.

FIG. 16 shows MIC microbroth dilution activity assays measuring the effect of H2B10, a representative of herein claimed domain swapped endolysins, on the growth of three main species of *Gardnerella*. *Gardnerella* suspensions at 1×10^5 - 1×10^6 CFU/ml were incubated with the concentration of H2B10 as indicated on the x-axis of each graph and incubated for 48h at 37°C under anaerobic conditions. Cell growth was evaluated by OD(610) measurements before and after the incubation to determine the Minimum Inhibitory Concentration (MIC). MIC values between 1 and 4µg/ml were obtained indicating that all *Gardnerella* strains are highly sensitive to the domain swapped endolysin H2B10.

DETAILED DESCRIPTION

Definitions

[0059] The term “lysins” refers to cell-wall lytic enzymes encoded by bacteriophages (endolysins) or bacteria (autolysins) which have the ability to hydrolyze the cell-wall of target bacteria when added exogenously (lysis-from-without). This novel class of antibacterials has important advantages over classical antibiotics, *e.g.* a novel mode of action; a narrow spectrum of susceptible bacteria; rapid killing of both stationary- and exponentially-growing bacteria; activity on mucous membranes and bacterial biofilms; low probability of developing resistances; and reduced impact on normal microbiota. These unique features have boosted the interest on the biotechnological and pharmacological exploitation of lysins and their recent inclusion among the top current alternatives to fight antibiotic resistances. Lysins from Gram-positive bacteria and their phages usually comprise at least one catalytic domain and one or more cell wall-binding domains. In contrast, many lysins produced by Gram-negative species or their phages only contain the catalytic domain, though modular endolysins have also been reported. The catalytic units dictate the type of peptidoglycan (PG) bond to be cleaved, whereas the cell wall-binding domain(s) largely determines the lytic spectrum by specific recognition of cell wall elements distributed in genus-, or species/strain-specific manner.

[0060] In the context of the present disclosure, the term “natural endolysin” refers to an endolysin encoded by a prophage sequence within a bacterial genome, in particular within the genome of *Gardnerella* cells. In the context of the present disclosure, the term “natural endolysin” therefore refers to an endolysin which has not been domain-swapped. A natural endolysin can be unmodified, meaning that the amino acid sequence of the endolysin corresponds to the native sequence. Alternatively, a natural endolysin can be modified, meaning that the amino acid sequence of the endolysin comprises at least one mutation compared to the native sequence. The amino acid sequences of natural endolysins E1-E14 are shown in Table 7, below. An example of a known 1, 4-beta-N-acetylmuramidase (natural endolysin EL1) sequence is also provided under NCBI accession No. WP_014554482 (version WP_014554482.1 of May 27, 2013).

[0061] In the context of the present disclosure, the term “recombinant endolysin” refers to an endolysin which has been domain-swapped. In the context of the present disclosure, the term “domain-swapped endolysin” refer to an endolysin which possess a N-terminal catalytic

domain from a first natural endolysin, and at least one cell-wall binding domain from a second natural endolysin, wherein the first and the second natural endolysin are encoded by different genomes from different prophages. A recombinant endolysin of the invention might comprise or consist of a N-terminal catalytic domain from a first natural endolysin, and two cell-wall binding domains from a second natural endolysin, wherein the first and the second natural endolysin are encoded by different genomes from different prophages. Alternatively, recombinant endolysin of the invention might comprise or consist of a N-terminal catalytic domain from a first natural endolysin, a first (N-terminal) cell-wall binding domain from a second natural endolysin, and a second (C-terminal) cell-wall binding domain from a third natural endolysin wherein the first and the second natural endolysin are encoded by different genomes from different prophages, and wherein the third natural endolysin is optionally encoded by a different genome from different a prophage than the first and the second natural endolysin. A recombinant endolysin can be unmodified, meaning that the amino acid sequence of the endolysin corresponds to the native sequence of the respective domains composing the endolysin. Alternatively, a recombinant endolysin can be modified, meaning that the amino acid sequence of the endolysin comprises at least one mutation compared to the native sequence of the respective domains composing the endolysin. In line with this definition, the person skilled in the art readily understands that the “domain-swapped” or “recombinant” endolysins as described herein are non-naturally occurring endolysins. That is, the recombinant endolysin of the present invention has been modified by hand of man and excludes, by definition, natural endolysins, i.e. as it can be naturally found in nature. The appended examples provide suitable method(s) how to generate the artificial endolysin of the invention.

[0062] The terms “catalytic domain” or “enzymatic domain” refer to the part of the protein chain which contains the region where the catalyzed chemical reaction takes place. In the context of the present disclosure the term “H-domain” refers to a part of an endolysin of the invention which contains a catalytic domain.

[0063] In the context of the present disclosure the term “B-region” refers to a part of an endolysin of the invention which comprises or consists of a polypeptide having a cell-wall binding activity. In a preferred embodiment, the B-region comprises or consists of a linker region and one, two or three cell-wall binding domains or “B-domains”.

[0064] In the context of the present invention the term “B-domain” refers to a cell-wall binding domain contained within the B-region.

[0065] In the context of the present disclosure the term “CW_7 domain” refers to a cell-wall binding domain of the protein Cpl-7, i.e. the endolysin encoded by the *Streptococcus*

pneumoniae bacteriophage Cp-7, (see Bustamante et al., 2010 J. Biol. Chem. 285, 33184–33196, 2012 PLoS One 7, e46654). Briefly, the Cpl-7 protein has a C-terminal cell-wall binding region composed of 3 consecutive CW_7 domains. Each CW_7 domains is composed of a similar amino acid sequence of 38 amino acids long, called the “CW_7 motif” and defined by Interpro (Mitchell *et al.*, 2019, Nucleic Acids Res. 47, D351–D360) as consisting of the amino acid sequence TVANEVIQGLWGNGQERYDSLANAGYDPQAVQDKVNEXL, wherein X is I in the CW_7 motifs No:1 (amino acids 207-245) and No:2 (amino acids 255-293) and wherein X is L in the CW_7 motif No:3 (amino acids 303-341). In the Cpl-7 protein, there are short, 9 residues linkers between the CW_7 motifs No:1 and No:2 and between the CW_motifs No:2 and No:3, so that the total repeat is 47 residues long. In comparison, the repeats of the natural endolysins of the present invention are 49 residues long.

[0066] The terms “Minimum Inhibitory Concentration” or “MIC” refer to the lowest concentration of a chemical, usually a drug, which prevents visible growth of bacterium. MIC was defined in the present application as the minimal concentration of antibiotic at which no growth was detectable after 48h by OD measurement.

[0067] The terms “Minimum Bactericidal Concentration” or “MBC” refer to the lowest concentration of an antibacterial agent required to kill a particular bacterium. Usually, the MBC₉₀ is measured, i.e. the antibiotic concentration killing 90% of cells within a defined time, while MBC has been defined in the present application as the minimal concentration fully eradicating a suspension of 2.5×10^7 CFU/ml. While MIC is the lowest concentration of an antibacterial agent necessary to inhibit visible growth, MBC is the minimum concentration of an antibacterial agent that results in bacterial death of all cells in suspension.

[0068] The terms “peptide”, “polypeptide”, “protein” and variations of these terms refer to peptide, oligopeptide, oligomer or protein including fusion protein, respectively, comprising at least two amino acids joined to each other by a normal or modified peptide bond, such as in the cases of the isosteric peptides, for example. These terms also include herewith “peptidomimetics” which are defined as peptide analogs containing non-peptidic structural elements, which peptides are capable of mimicking or antagonizing the biological action(s) of a natural parent peptide. A peptidomimetic lacks classical peptide characteristics such as enzymatically scissile peptide bonds. A peptide or polypeptide can be composed of amino acids other than the 20 amino acids defined by the genetic code. It can be composed of L-amino acids and/or D-amino acids. A peptide or polypeptide can equally be composed of amino acids modified by natural processes, such as post-translational maturation processes or by chemical processes, which are well known to a person skilled in the art. Such modifications are fully

detailed in the literature. These modifications can appear anywhere in the polypeptide: in the peptide skeleton, in the amino acid chain or even at the carboxy- or amino-terminal ends. A peptide or polypeptide can be branched following an ubiquitination or be cyclic with or without branching. This type of modification can be the result of natural or synthetic post-translational processes that are well known to a person skilled in the art. For example, peptide or polypeptide modifications can include acetylation, acylation, ADP-ribosylation, amidation, covalent fixation of a nucleotide or of a nucleotide derivative, covalent fixation of a lipid or of a lipidic derivative, the covalent fixation of a phosphatidylinositol, covalent or non-covalent cross-linking, cyclization, disulfide bond formation, demethylation, glycosylation including pegylation, hydroxylation, iodization, methylation, myristoylation, oxidation, proteolytic processes, phosphorylation, prenylation, racemization, seneloylation, sulfatation, amino acid addition such as arginylation or ubiquitination. Such modifications are fully detailed in the literature and well-known by the skilled person of the art.

[0069] As used herewith “bacterial infections and disorders” refer to infections and disorders caused by bacteria, in particular infections and disorders caused by at least one strain of the *Gardnerella* genus selected from the group consisting of *Gardnerella vaginalis sensu strict*, *Gardnerella leopoldii*, *Gardnerella piovani* and *Gardnerella swidsinskii*, and other *Gardnerella* species. Bacterial infections and disorders include but are not limited to Bacterial Vaginosis (BV).

[0070] As defined herewith the terms “killing activity” of an endolysin against a particular bacteria represents a reduction in the number of viable bacteria cells caused by the lysing activity of said endolysin. The killing activity of the endolysin against said bacteria can be complete meaning that 100% of the bacterial cells have been lysed or partial meaning that at least about 80%, at least about 90%, at least about 95%, at least about 99%, or at least about 99.9% of the bacterial cells have been lysed. Killing activity can be determined by measuring a decrease in optical density at 610-620 nm of a bacterial cell suspension and/or a decrease in Colony Forming Units (CFU) per millilitre of a bacterial cell suspension after exposure to the endolysin to be tested.

[0071] As defined herewith the terms “binding capacity” of an endolysin to the cell wall of a particular bacteria refers to the ability of said endolysin to specifically interact and adhere to the cell wall of said bacteria. The binding capacity of an endolysin to the cell wall of a bacteria can be determined by methods known of the art.

[0072] As used herein, “treatment” and “treating” and the like generally mean obtaining a desired pharmacological and physiological effect. The effect may be prophylactic in terms of

preventing or partially preventing a disease, symptom or condition thereof and/or may be therapeutic in terms of a partial or complete cure of a disease, condition, symptom or adverse effect attributed to the disease. The term “treatment” as used herein covers any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; or relieving the disease, i.e., causing regression of the disease and/or its symptoms or conditions such as improvement or remediation of damage. In particular, treatment of bacterial infections comprises preventing, decreasing or even eradicating the infection, for instance by killing the bacteria and, thus, controlling, reducing or inhibiting bacterial proliferation as well as reducing the number of viable bacterial cells. Herein it is preferred that the disease, e.g. BV is treated therapeutically in terms of a partial or complete cure of the disease or the symptoms.

[0073] The term “subject” as used herein refers to mammals. For examples, mammals contemplated by the present invention include human, primates, domesticated animals such as cattle, sheep, pigs, horses, laboratory rodents and the like. It is preferred that the subject is a human being.

[0074] The term "effective amount" as used herein refers to an amount of at least one endolysin according to the invention, composition or pharmaceutical formulation thereof, that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought. In one embodiment, the effective amount is a "therapeutically effective amount" for the alleviation of the symptoms of the disease or condition being treated. In another embodiment, the effective amount is a "prophylactically effective amount" for prophylaxis of the symptoms of the disease or condition being prevented. The term also includes herein the amount of active polypeptide sufficient to reduce the progression of the disease, notably to reduce or inhibit the disorder or infection and thereby elicit the response being sought (i.e. an "inhibition effective amount").

[0075] The term “efficacy” of a treatment according to the invention can be measured based on changes in the course of disease in response to a use or a method according to the invention. The efficacy of prevention of infectious disease is ultimately assessed by epidemiological studies in human populations, which often correlates with titers of neutralizing antibodies in sera, and induction of multifunctional pathogen specific T cell responses. Preclinical assessment can include resistance to infection after challenge with infectious pathogen. Treatment of an infectious disease can be measured by inhibition of the pathogen’s growth or elimination of the pathogen (and, thus, absence of detection of the pathogen),

correlating with pathogen specific antibodies and/or T cell immune responses.

[0076] The term “biological material” refers to any material or sample that is obtained from a subject’s body. This includes, for instance, samples of whole blood, serum, plasma, urine, sputum, saliva, vaginal swabs, or spinal fluids.

[0077] The term “inanimate material or surface” includes solutions, medium, devices, objects, floor, surface of a table.

[0078] The term “medium” includes water, air or food.

[0079] The terms “pharmaceutical formulation” or “pharmaceutical composition” refer to preparations which are in such a form as to permit biological activity of the active ingredient(s) to be unequivocally effective and which contain no additional component which would be toxic to subjects to which the said formulation would be administered.

[0080] The term “pharmaceutically acceptable” refers to a carrier comprised of a material that is not biologically or otherwise undesirable.

[0081] The term “carrier” refers to any components present in a pharmaceutical formulation other than the active agent and thus includes diluents, binders, lubricants, disintegrants, fillers, coloring agents, wetting or emulsifying agents, pH buffering agents, preservatives and the like.

[0082] The term “variant” refers to a polypeptide including insertions, deletions, and/or substitutions, either non-conservative or preferably conservative, relative to the native amino acid sequence. For example, the polypeptide may comprise an amino acid sequence with at least 80% identity to the native amino acid sequence, preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity to said amino acid sequence. Percent identity can be determined by methods well known in the art, using suitable computer programs for example MatGAT 2.0 (*Myers and Miller, CABIOS (1989)*) Preferably, % identity is identified over the whole lengths of the sequences to be compared. It will be appreciated that percent identity is calculated in relation to polypeptides whose sequence has been aligned optimally. Fragment and variants of an amino acid sequence may be made using any of the methods of protein engineering, directed evolution and/or site-directed mutagenesis well known in the art (for example, see *Molecular Cloning: a Laboratory Manual, 3rd edition, Sambrook & Russell, 2001, Cold Spring Harbor Laboratory Press*). It will be appreciated by skilled persons that a polypeptide according to the invention, or fragment, variant, or fusion thereof, may comprise or

consist of a derivative of a native amino acid sequence, or a fragment or variant thereof. Chemical derivatives of one or more amino acids may be achieved by reaction with a functional side group. Such derivatised molecules include, for example, those molecules in which free amino acid groups have been derivatised to form amine hydrochlorides, *p*-toluene sulphonyl groups, carboxybenzoxy groups, *t*-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatised to form salts, methyl and ethyl esters or other types of esters and hydrazides. Free hydroxyl groups may be derivatised to form O-acyl or O-alkyl derivatives. Also included as chemical derivatives are those peptides which contain naturally occurring amino acid derivatives of the twenty standard amino acids. For example: 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine and ornithine for lysine. Derivatives also include peptides containing one or more additions or deletions as long as the requisite activity is maintained. Other included modifications are amidation, amino terminal acylation (*e.g.*, acetylation or thioglycolic acid amidation), terminal carboxylamidation (*e.g.*, with ammonia or methylamine), and the like terminal modifications. It will be further appreciated by persons skilled in the art that peptidomimetic compounds may also be useful. Thus, by 'polypeptide' we include peptidomimetic compounds which exhibit endolysin activity. The term 'peptidomimetic' refers to a compound that mimics the conformation and desirable features of a particular polypeptide as a therapeutic agent.

Endolysins according to the invention

[0083] The endolysin of the present invention has an antibacterial activity against *Gardnerella* strains. The optimum pH at which the endolysin according to the invention exhibits an antibacterial activity is comprised between about 4 and 6, preferably a pH about 5.

The endolysin of the present invention comprises or consists of

- (i) a N-terminal catalytic domain, or a functional variant thereof;
 - (ii) a C-terminal cell-wall binding region, or a functional variant thereof, wherein the C-terminal cell-wall binding region comprises or consists of at least one cell-wall binding domain; and
 - (iii) a linker region between the N-terminal catalytic domain and the C-terminal cell-wall binding region,
- and has a killing activity against *Gardnerella* cells.

In some embodiment, the N-terminal catalytic domain is from a first natural endolysin, the linker region and the C-terminal cell-wall binding region are from a second natural endolysin, and the

first and the second natural endolysin are encoded by different genomes from different prophages. It is envisaged that the killing activity of the endolysins of the invention against *Gardnerella* is a species-selective killing activity against *Gardnerella*.

[0084] The N-terminal catalytic domain is a functional polypeptide, wherein the function comprises the ability to lyse the cell wall of *Gardnerella*. The N-terminal catalytic domain may be a N-acetylmuramidase, N-acetylmuramoyl-L-alanine amidases, L-alanoyl-D-glutamate endopeptidases, interpeptide bridge endopeptidases or N-acetyl-beta-D-glucosaminidases. Preferably, the N-terminal catalytic domain is a N-acetylmuramidase, most preferably a 1,4-beta-N-acetylmuramidase. For example, the N-terminal catalytic domain may be a polypeptide comprising or consisting of the amino acid of any one of SEQ ID NOs: 1 to 5, 7, or 10 to 12 or any variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of any one of SEQ ID NOs: 1 to 5, 7, or 10 to 12, whereby said polypeptide is functional, wherein the function comprises the ability to lyse the cell wall of *Gardnerella*. Preferably, the N-terminal catalytic domain is a polypeptide comprising the amino acid of SEQ ID NOs: 2 or 7 or any variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NOs: 2 or 7, whereby said polypeptide is functional, wherein the function comprises the ability to lyse the cell wall of *Gardnerella*.

[0085] According to the present invention the C-terminal cell-wall binding region is a functional polypeptide, wherein the function comprises the ability to bind to the cell wall of *Gardnerella*. The C-terminal cell-wall binding region may comprise or consist of one, two, three or more cell-wall binding domains. For example, the one, two, three or more cell-binding domains may be independently selected from the group consisting of the polypeptides comprising or consisting of the amino acid sequence of SEQ ID NOs: 15 to 24 and 26 to 33, respectively, and any variants thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more

preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of SEQ ID NOs: 15 to 24 and 26 to 33, respectively, whereby said polypeptides are functional, wherein the function comprises the ability to bind to the cell wall of *Gardnerella*. Preferably, the one, two, three or more cell-wall binding domains are independently selected from the group consisting of a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 19, 20 and 28-33 or any variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of any one of SEQ ID NOs: 19, 20 and 28-33, whereby said polypeptide is functional, wherein the function comprises the ability to bind to the cell wall of *Gardnerella*. More preferably, the one, two, three or more cell-wall binding domains are independently selected from the group consisting of a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 28-33 or any variant thereof having at least 80% identity (preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, and most preferably at least 99.7% identity) with the amino acid sequence of any one of SEQ ID NOs: 28-33, whereby said polypeptide is functional, wherein the function comprises the ability to bind to the cell wall of *Gardnerella*.

Most preferably, the C-terminal cell-wall binding region comprises a first cell-wall binding domain and a second cell-wall binding domain, wherein said first cell-wall binding domain is selected from the group consisting of SEQ ID NOs: 15, 17, 19, 21, 23, 26, 28, 30 and 32, and said second cell-wall binding domain is selected from the group consisting of SEQ ID NOs: 16, 18, 20, 22, 24, 27, 29, 31 and 33. In preferred embodiments, said first cell-wall binding domain is N-terminally of said second cell-wall binding domain.

[0086] In one aspect of the invention, the linker region consists of a polypeptide having a length of 6 to 18 amino acids, preferably a length of 9 to 15 amino acids, even more preferably a length of 12 amino acids. Preferably, the linker region consists of a polypeptide comprising or consisting of the amino acid sequence (i) (XXX)_n, wherein each X can be independently G, A or S, preferably wherein the amino acid sequence (XXX)_n is (GGS)_n, wherein n corresponds to the number of repetitions of the sequence XXX, preferably wherein n is 2, 3, 4, 5 or 6, or (ii)

X₁X₂GLNGX₃X₄NGGS, wherein X₁ is N or K, X₂ is A or V, X₃ is Y or C and X₄ is K or Q. The fragment comprising the linker may be absent. The fragment comprising the linker may also be present and may enhance the cell wall binding and/or lytic activity of the polypeptide of the invention.

[0087] The invention further provides an endolysin having a killing activity against *Gardnerella* as described above for use in treating a disease or disorder. The disease or disorder to be treated may be a bacterial infection, preferably bacterial vaginosis. The bacterial vaginosis may be caused by *G. vaginalis sensu stricto*, *G. leopoldii*, *G. piovii*, and/or *G. swidsinskii*, or other species of the genus *Gardnerella*.

[0088] The endolysin of the invention is preferably capable of binding specifically to and/or lysing cells of *Gardnerella* for use in a method of treating a *Gardnerella* infection such as BV.

[0089] As noted above, it is well established that many bacteriophage endolysins consist of two distinct domains (for example, see Sheehan *et al.*, 1996, *FEMS Microbiology Letters* 140:23-28). One is a catalytic domain that is responsible for cell wall degradation and these are known to exist in several forms. The other domain is a cell-wall binding domain that recognizes a cell surface motif and permits attachment of the endolysins to that target cell. The precise pattern recognition involved in the latter is what provides the specificity. The enzymatic domain can be identified by its amino acid homology to other similar regions of lytic enzymes that share the same type of lytic activity. In the case of the natural *Gardnerella* prophage endolysins newly discovered by the inventors, the domain arrangement has been identified to consist of a N-terminal domain of 196 residues, followed by a linker region of 12 residues and two repeated domains of respectively 49 residues, except for EL6 and EL9 where there is only one incomplete domain of 43 residues. The native amino acid sequences of these newly discovered endolysins are summarized in Table 7. The inventors identified that the N-terminal domain is the catalytic domain due to its homology to Glycoside hydrolases, family 25 and that the two repeated domains are two cell-wall binding domains due to their homology to the C-terminal domain of lysozyme Cpl-7 (see Example 2 and Fig. 3).

[0090] In some embodiment, the fragment comprising the enzymatic domain is unmodified, i.e. corresponds to the native amino acid sequence. In an alternative embodiment, the fragment comprising the enzymatic domain may comprise alterations such as substitution, deletion, insertion of amino acids or any combination of alteration thereof. In some embodiment the fragment comprising the enzymatic domain is a variant fragment having at least 80%, preferably at least 85% identity, more preferably at least 90% identity, even more preferably at

least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, even more preferably at least 99.7% identity, and most preferably 100% identity with the amino acids sequences of any one of SEQ ID NOs: 1 to 5, 7, or 10 to 12.

[0091] In some embodiment, the fragment comprising the cell-wall binding domain is unmodified, i.e. corresponds to the native amino acid sequence. In an alternative embodiment, the fragment comprising the enzymatic domain may comprise alterations such as substitution, deletion, insertion of amino acids or any combination of alteration thereof. In some embodiment the fragment comprising the cell-wall binding domain is a variant fragment having at least 80%, preferably at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, even more preferably at least 96% identity, even more preferably at least 97% identity, even more preferably at least 98% identity, even more preferably at least 99% identity, even more preferably at least 99.5% identity, even more preferably at least 99.7% identity, and most preferably 100% identity with the amino acids sequences of any one of SEQ ID NOs: 15 to 24 and 26 to 33.

[0092] In a further aspect of the invention, the endolysin comprises or consists of a fusion of a polypeptide, or a fragment, variant, or derivative thereof. By “fusion” of a polypeptide we include a polypeptide which is fused to any other polypeptide. For example, the polypeptide may comprise one or more additional amino acids, inserted internally and/or at the N- and/or C-termini of the amino acid sequence of an endolysin according to the invention, or of a fragment, variant or derivative thereof.

Thus, as described above, in one embodiment the endolysin of the first aspect of the invention comprises a fragment consisting of one or more cell-wall binding domains comprising or consisting of the amino acid sequence of any one of SEQ ID NO: 15 to 24 and 26 to 33 (or a variant of such a domain sequence which retains the cell-wall binding activity thereof), respectively, to which is fused an enzymatic domain from a different source. Examples of other suitable enzymatic domains include but are not limited to L-alanoyl-D-glutamate endopeptidase, D-glutamyl-m-DAP endopeptidase, interpeptide bridge-specific endopeptidase, V-acetyl- β -D-glucosaminidase (muramoylhydrolase), *N*-acetyl- β -D-muramidase (lysozyme) or lytic transglycosylase. Also N-acetylmuramoyl-L-alanine amidase from other sources could be utilized.

[0093] In one aspect of the invention, the endolysin may be fused to a polypeptide or protein in order to facilitate purification of said endolysin. Examples of such fusions are well

known to those skilled in the art. Similarly, the endolysin may be fused to an oligo-histidine tag such as His6 or to an epitope recognized by an antibody such as well-known Myc tag epitope. Fusions to any fragment variant or derivative of an endolysin according to the present invention are also included in the scope of the invention. It will be appreciated that fusions (or variants or derivatives thereof) which retain desirable properties, namely endolysin activity are preferred. It is also particularly preferred if the fusions are ones which are suitable for use in methods described herein. For example, the fusion may comprise a further portion which confers a desirable feature on the endolysin of the invention; for example, the portion may be useful in detecting or isolating the endolysin, promoting cellular uptake of the endolysin, or directing secretion of the protein from a cell. The portion may be, for example, a biotin moiety, a radioactive moiety, a fluorescent moiety, for example a small fluorophore or a green fluorescent protein (GFP) fluorophore, as well known to those skilled in the art. The moiety may be an immunogenic tag, for example a Myc tag, as known to those skilled in the art or may be a lipophilic molecule or polypeptide domain that is capable of promoting cellular uptake of the endolysin, as known to those skilled in the art.

[0094] An essential feature of the endolysins of the invention is the ability to lyse cells of *Gardnerella* genus. Preferably, the endolysin is capable of lysing cells of multiple strains of *Gardnerella*. Most preferably, the endolysin is capable of lysing all strains of the genus *Gardnerella*, including *G. vaginalis sensu stricto*, *G. leopoldii*, *G. piovii* and *G. swidsinskii* (Vanechoutte et al., 2019 Int. J. Syst. Evol. Biol. 898661). In one embodiment, the endolysins of the invention are substantially or completely incapable of lysing bacteria which are commensal members of the microbiota of a healthy vagina (and not known to cause adverse effects on the host). For example, it is advantageous if the endolysins do not lyse cells of *Lactobacilli* genus. Most preferably, the endolysins of the invention are substantially or completely incapable of lysing cells of *L. crispatus*, *L. gasseri* and *L. jensenii*. Optionally, the endolysins of the invention do not lyse cells of *L. iners*. Advantageously, the endolysin is capable of lysing cells of pathogenic bacteria selectively, i.e. to a greater extent than cells of non-pathogenic bacteria.

[0095] The killing activity of an endolysin according to the invention on a particular microorganism may be determined by standard procedures in the field including those based on the determination of the Minimum Inhibitory Concentrations (MICs) of an antimicrobial agent defined as the lowest concentration of said antimicrobial agent that inhibits the visible growth of a microorganism after overnight incubation as described in *Andrews, 2001, J Antimicrobial Chemotherapy*, 48, Suppl. SI, 5-16 or in “*Document M7-A7, Methods for dilution antimicrobial*

susceptibility tests for bacteria that grow aerobically; Approved standards, 7th Edition, January 2006, vol. 26, No. 2 published by Clinical and Laboratory Standards Institute. Another suitable method for determining the killing activity of an endolysin according to the invention is described in the example section of the present application and consists in determining the decrease of the Optical Density measured at 610-620 nm of a suspension of the bacteria the susceptibility of which is to be tested in an *in vitro* turbidity assay performed in presence of purified endolysin according to the invention. According to another embodiment, in an *in vitro* turbidity test as described herewith, an endolysin according to the invention decreases the OD(610-620 nm) of a suspension of at least one strain of *Gardnerella* bacteria by more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, or more than 95%.

[0096] Methods for the production of endolysins, or a fragment, variant, fusion, or derivative thereof, for use according to the invention are well known in the art. Conveniently, the endolysin, or fragment, variant, fusion or derivative thereof, is or comprises a recombinant endolysin. The endolysin according to the invention can be produced by standard techniques of genetic engineering comprising the use of a recombinant vector comprising a polynucleotide encoding an endolysin as described herewith. Numerous expression systems can be used including bacterial plasmids and derived vectors, transposons, yeast episomes, insertion elements, yeast chromosome elements, viruses such as baculovirus, papilloma viruses such as SV40, vaccinia viruses, adenoviruses, fox pox viruses, pseudorabies viruses, retroviruses, cosmid or phagemid derivatives. The nucleotide sequence can be inserted in the recombinant expression vector by methods well known to a person skilled in the art such as, for example, those that are described in MOLECULAR CLONING: A LABORATORY MANUAL, Sambrook et al., 4th Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001. The recombinant vector can include nucleotide sequences that control the regulation, the expression, the transcription, and/or the translation of the polynucleotide encoding the endolysin, these sequences being selected according to the host cells that are used. The recombinant vector can further include nucleotide sequences such as those encoding His tags for facilitating the purification step. Subsequently, such a recombinant vector is introduced in a host cell according to methods that are well known to a person skilled in the art, such as those described in BASIC METHODS IN MOLECULAR BIOLOGY, Davis et al., 2nd ed., McGraw-Hill Professional Publishing, 1995, and MOLECULAR CLONING: A LABORATORY MANUAL, supra, such as transfection by calcium phosphate, transfection by DEAE dextran, transfection, microinjection, transfection by cationic lipids, electroporation, transduction or infection. The

host cell can be, for example, bacterial cells such as *E. coli*, cells of fungi such as yeast cells and cells of *Aspergillus*, *Streptomyces*, insect cells, Chinese Hamster Ovary cells (CHO), C127 mouse cell line, BHK cell line of Syrian hamster cells, Human Embryonic Kidney 293 (HEK 293) cells. Preferably, the host cell is *E. coli*. Said host cells are then cultivated in appropriate conditions so as to produce the endolysin described herewith, which can then further be purified from the culture medium or from the host cell lysate by any standard purification methods including, Immobilized-Metal Affinity Chromatography (IMAC) (*Block et al. 2008, Protein Expr. Purif.* 27, 244-254).

Compositions according to the invention

[0097] In a further aspect of the invention are provided antibacterial compositions comprising an endolysin according to the first aspect of the invention, a nucleic acid according to the second aspect of the invention, a vector/plasmid according to the third aspect of the invention, a host cell according to the fourth aspect of the invention or a bacteriophage capable of expressing an endolysin according to the first aspect of the invention, in particular pharmaceutical compositions.

[0098] As used herein, “pharmaceutical composition” means a therapeutically effective formulation for use in the methods of the invention. A “therapeutically effective amount”, or “effective amount”, or “therapeutically effective”, as used herein, refers to that amount which provides a therapeutic effect for a given condition and administration regimen. This is a predetermined quantity of active material calculated to produce a desired therapeutic effect in association with the required additive and diluent, i.e. a carrier or administration vehicle. Further, it is intended to mean an amount sufficient to reduce, and most preferably prevent, a clinically significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in a host. As is appreciated by those skilled in the art, the amount of a compound may vary depending on its specific activity. Suitable dosage amounts may contain a predetermined quantity of active composition calculated to produce the desired therapeutic effect in association with the required diluent. In the methods and use for manufacture of compositions of the invention, a therapeutically effective amount of the active component is provided. A therapeutically effective amount can be determined by the ordinary skilled medical or veterinary worker based on patient characteristics, such as age, weight, sex, condition, complications, other diseases, *etc.*, as is well known in the art. In one embodiment of the invention, the pharmaceutical composition comprises an endolysin according to the first aspect of the

invention. Thus, the pharmaceutical formulation may comprise an amount of an endolysin, or fragment, variant, fusion or derivative thereof, sufficient to inhibit at least in part the growth of cells of the genus *Gardnerella* in a patient who is infected or susceptible to infection with such cells. Preferably, the pharmaceutical formulation comprises an amount of endolysin, or fragment, variant, fusion or derivative thereof, sufficient to kill cells of the genus *Gardnerella* in the patient. It will be appreciated by persons skilled in the art that the endolysins of the invention are generally administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice (for example, see *Remington: The Science and Practice of Pharmacy*, 19th edition, 1995, Ed. Alfonso Gennaro, Mack Publishing Company, Pennsylvania, USA). For example, the endolysins can be administered locally, i.e. locally into the vagina of a female subject and/or, in a male subject into or on the glans penis, prepuce or urethral entry. Herein the term “(administration) into or on the glans penis” also includes “(administration) into and on the glans penis”. In line with this, the term “(administration) into or on the glans penis, prepuce or urethral entry of a male subject” also includes “(administration) into and on the glans penis and on the prepuce and on the urethral entry of a male subject”. In another embodiment, the endolysins can be co-administered with a compound or composition which adjusts the pH of the vagina. In some embodiment the compound or composition adjusts the pH of the vagina to pH 4.0 to 6.0, preferably to pH 5.0.

In an alternative embodiment of the invention, the pharmaceutical compositions do not comprise the endolysin itself but instead comprise a nucleic acid molecule capable of expressing said endolysin. Suitable nucleic acid molecules, expression vectors, and host cells are described in detail above. For example, a recombinant probiotic may be used (LAB strain, *e.g.*, *Lactococcus lactis* or a *Lactobacillus sp.*). In a further embodiment of the invention, the pharmaceutical compositions comprise a bacteriophage capable of expressing an endolysin according to the first aspect of the invention. Methods for performing such bacteriophage-based therapies are well known in the art (for example, see Watanabe *et al.*, 2007, *Antimicrobial Agents & Chemotherapy* 51:446-452). Thus, for treatment of bacterial infections described herein, the endolysin of the invention may be administered as the cognate protein, as a nucleic acid construct, vector or host cell which expresses the cognate protein, as part of a living organism which expresses the cognate protein (including bacteriophages), or by any other convenient method known in the art so as to achieve contact of the endolysin with its bacterial target, whether that be a pathogenic bacterium, such as *G. vaginalis*, or another pathogen or potential pathogen, as further described herein.

[0099] Compositions of the invention can contain one or more endolysin polypeptides. In this embodiment, endolysin polypeptides can either be present as independent polypeptides or as fusion proteins comprising said endolysin polypeptides or fragments thereof.

[0100] Pharmaceutical compositions of this invention may further comprise one or more pharmaceutically acceptable additional ingredient(s) such as alum, stabilizers, antimicrobial agents, buffers, coloring agents, flavoring agents, adjuvants, and the like. It is preferred that the pharmaceutical composition of the invention does not comprise imidazole.

[0101] The endolysins of the invention, together with a conventionally employed adjuvant, carrier, diluent or excipient may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, aerosols, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Compositions of this invention may also be liquid formulations including, but not limited to, aqueous or oily suspensions, solutions, emulsions, syrups, and elixirs. The compositions may also be formulated as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain additives including, but not limited to, suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. Suspending agents include, but are not limited to, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats. Emulsifying agents include, but are not limited to, lecithin, sorbitan monooleate, and acacia. Nonaqueous vehicles include, but are not limited to, edible oils, almond oil, fractionated coconut oil, oily esters, propylene glycol, and ethyl alcohol. Preservatives include, but are not limited to, methyl or propyl p-hydroxybenzoate and sorbic acid. Further materials as well as processing techniques and the like are set out in Part 5 of *Part 5 of Remington's "The Science and Practice of Pharmacy", 22nd Edition, 2012, University of the Sciences in Philadelphia, Lippincott Williams & Wilkins.*

[0102] Solid compositions of this invention may be in the form of tablets or lozenges formulated in a conventional manner. Tablets may be coated according to methods well known in the art. Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art.

[0103] Compositions of this invention may also be formulated as suppositories, which may contain suppository bases including, but not limited to, cocoa butter or glycerides. Compositions of this invention may also be formulated transdermal formulations comprising aqueous or non-aqueous vehicles including, but not limited to, creams, ointments, lotions, pastes, medicated plaster, patch, or membrane.

[0104] Compositions of this invention may also be formulated for parenteral administration including, but not limited to, by injection or continuous infusion. Formulations for injection may be in the form of suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents including, but not limited to, suspending, stabilizing, and dispersing agents. The composition may also be provided in a powder form for reconstitution with a suitable vehicle including, but not limited to, sterile, pyrogen-free water.

[0105] Compositions of this invention may also be formulated as a depot preparation, which may be administered by implantation or by intramuscular injection. The compositions may be formulated with suitable polymeric or hydrophobic materials (as an emulsion in an acceptable oil, for example), ion exchange resins, or as sparingly soluble derivatives (as a sparingly soluble salt, for example).

[0106] The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can also be found in *Remington's "The Science and Practice of Pharmacy"*.

Method of administration

[0107] Compositions of this invention are preferably administered locally into the vagina of a female subject and/or into or on the glans penis, prepuce or urethral entry of a male subject. However, these compositions may also be administered in any manner including intravenous injection, intra-arterial, intraperitoneal injection, subcutaneous injection, intramuscular, intra-theal, oral route including sublingually or via buccal administration, topically, cutaneous application, direct tissue perfusion during surgery or combinations thereof.

[0108] In a preferred embodiment the endolysins, polynucleotides or pharmaceutical compositions of the present invention as described herein are to be administered locally. In a further preferred embodiment the endolysins, polynucleotides or pharmaceutical compositions of the present invention as described herein are to be administered into the vagina of a female subject and/or into or on the glans penis, prepuce or urethral entry of a male subject. In a further preferred embodiment the endolysins, polynucleotides or pharmaceutical compositions of the present invention as described herein are to be administered locally into the vagina of a subject.

[0109] The dosage administered, as single or multiple doses, to an individual will vary depending upon a variety of factors, including pharmacokinetic properties, patient conditions and characteristics (sex, age, body weight, health, size), extent of symptoms, concurrent treatments, frequency of treatment and the effect desired.

[0110] According to one aspect, the compositions of the invention may be administered in a preventive manner to patients before sexual relations.

Combination

[0111] According to the invention, an endolysin can be administered alone or in combination with a co-agent useful in the prevention and/or treatment of *Gardnerella* infections or disorders, including those caused by *Gardnerella vaginalis sensu stricto*, *Gardnerella leopoldii*, *Gardnerella piovii*, *Gardnerella swidsinskii* and/or other species of the genus *Gardnerella*.

[0112] An endolysin according to the invention can be administered in combination with

- (a) one or more conventional antibiotic treatments. Such antibiotics may include Clindamycin, Metronidazole or any other suitable antibiotics known by a skilled person in the art;
- (b) one or more additional endolysins, or nucleic acid molecules, vectors, host cell or bacteriophage capable of expressing the same;
- (c) a compound or composition adjusting the pH of the vagina. In some embodiment the compound or composition adjusts the pH of the vagina to pH 4.0 to 6.0, preferably to pH 5.0. Suitable pH adjusting compounds may include phosphate, lactic acid (e.g. the natural acidification substance which *Lactobacilli* secrete to establish an acidic milieu) or other organic acids, e.g. carboxy-substituted polymers;
- (d) a therapy to neutralize the toxins released upon bacterial lysis of *Gardnerella* cells within the vagina. Suitable neutralising therapies may include antibodies (see Babcock *et al.*, 2006, *Infect. Immun.* 74:6339-6347) and toxin absorbing agents such as tolevamer (see Barker *et al.*, 2006, *Aliment. Pharmacol. Ther.* 24:1525-1534);
- (e) a probiotic.

Uses and methods according to the invention

[0113] A further aspect of the invention provides an endolysin according to the invention, a nucleic acid according to the invention, a vector according to the invention, a host cell according to the invention, a bacteriophage capable of expressing an endolysin according to the invention, or a pharmacological composition according to the invention for use in medicine.

Hence, the endolysins of the invention may be for use in a method for treatment of the human or animal body by surgery or therapy and/or diagnostic methods practiced on the human or animal body. In particular, the invention provides an endolysin according to the invention, a nucleic acid of the invention, a vector/plasmid of the invention, a host cell of the invention, a bacteriophage capable of expressing an endolysin of the invention, or a pharmacological composition of the invention for use in treating a disease or disorder.

[0114] A further aspect of the invention provides an endolysin of the invention, a nucleic acid of the invention, a vector/plasmid of the invention, a host cell of the invention, a bacteriophage capable of expressing an endolysin of the invention, or a pharmacological composition according to the invention for use as a medicament.

[0115] An further aspect of the invention provides the use of a endolysin of the invention, a nucleic acid of the invention, a vector/plasmid of the invention, a host cell of the invention, a bacteriophage capable of expressing an endolysin of the invention, or a pharmacological composition of the invention, in the preparation of a medicament for killing and/or inhibiting/preventing the growth of microbial cells in a patient, wherein the microbial cells are selected from the group consisting of *Gardnerella* cells and other bacterial cells susceptible to lysis with said endolysin. In particular, the invention provides the use of a endolysin of the invention, a nucleic acid of the invention, a vector/plasmid of the invention, a host cell of the invention, a bacteriophage capable of expressing an endolysin of the invention, or pharmacological composition of the invention, in the manufacture of a medicament for treating bacterial infections and disorders.

[0116] A further aspect of the invention provides an endolysin of the invention, a nucleic acid of the invention, a vector/plasmid of the invention, a host cell of the invention or a pharmacological composition of the invention for use in killing and/or inhibiting/preventing the growth of microbial cells in a patient, wherein the microbial cells are selected from the group consisting of *Gardnerella* cells and other bacterial cells susceptible to lysis with said endolysin.

[0117] A further aspect of the invention provides a method for killing and/or inhibiting/preventing the growth of microbial cells in a patient the method comprising administering to the patient an endolysin of the invention, a nucleic acid of the invention, a vector/plasmid of the invention, a host cell of the invention, a bacteriophage capable of expressing an endolysin of the invention or pharmacological composition of the invention, wherein the microbial cells are selected from the group consisting of *Gardnerella* cells and other bacterial cells susceptible to lysis with said endolysin.

[0118] An further aspect of the invention provides the use of an endolysin of the

invention, a nucleic acid of the invention, a vector/plasmid of the invention, a host cell of the invention, a bacteriophage capable of expressing an endolysin of the invention or a pharmacological composition of the invention in the preparation of a medicament for the treatment or prevention of a disease or condition associated with microbial cells in a patient, wherein the microbial cells are selected from the group consisting of *Gardnerella* cells and other bacterial cells susceptible to lysis with said endolysin.

[0119] A further aspect of the invention provides an endolysin of the invention, a nucleic acid of the invention, a vector/plasmid of the invention, a host cell of the invention, a bacteriophage capable of expressing an endolysin of the invention or a pharmacological composition of the invention for use in the treatment or prevention of a disease or condition associated with microbial cells in a patient, wherein the microbial cells are selected from the group consisting of *Gardnerella* cells and other bacterial cells susceptible to lysis with the endolysins of the invention.

[0120] A further aspect of the invention provides a method for the treatment or prevention of a disease or condition associated with microbial cells in a patient in need of such treatment, the method comprising administering to the patient an endolysin of the invention, a nucleic acid of the invention, a vector/plasmid of the invention, a host cell of the invention, a bacteriophage capable of expressing an endolysin of the invention or a pharmacological composition of the invention, wherein the microbial cells are selected from the group consisting of *Gardnerella* cells and other bacterial cells susceptible to lysis with the endolysins of the invention.

[0121] “A disease or condition associated with microbial cells in a patient” includes diseases and conditions arising from or antagonised by infection of a patient with *Gardnerella*. Such diseases and conditions include BV.

[0122] By ‘treatment’ we include both therapeutic and prophylactic treatment of a subject (or patient). In one embodiment, the endolysin of the invention, nucleic acid of the invention, vector/plasmid of the invention, host cell of the invention, bacteriophage capable of expressing an endolysin of the invention or the pharmacological composition of the invention, uses and methods of the invention are for the treatment of an existing disease or condition. Alternatively or additionally, the uses and methods of the invention may be for prophylaxis. The term ‘prophylactic’ or ‘prophylaxis’ is used to encompass the use of an endolysin or composition described herein which either prevents or reduces the likelihood of infection with *Gardnerella* in a patient or subject. The prophylaxis may be primary prophylaxis (i.e., to prevent the development of a disease) or secondary prophylaxis (where the disease has already developed

and the patient is protected against worsening of this process). It is preferred that the means and methods provided herein are for the treatment of an existing disease or condition, particularly for the treatment of an existing BV.

[0123] As discussed above, the term ‘effective amount’ is used herein to describe concentrations or amounts of endolysins according to the present invention which may be used to produce a favourable change in a disease or condition treated, whether that change is a remission, a favourable physiological result, a reversal or attenuation of a disease state or condition treated, the prevention or the reduction in the likelihood of a condition or disease state occurring, depending upon the disease or condition treated. In one embodiment, the endolysin according to the first aspect of the invention, nucleic acid according to the second aspect of the invention, vector according to the third aspect of the invention, host cell according to the fourth aspect of the invention, bacteriophage capable of expressing an endolysin according to the first aspect of the invention or pharmacological composition according to the sixth aspect of the invention is administered in a single dose. Alternatively, the endolysin, nucleic acid, vector/plasmid, host cell, bacteriophage or pharmacological composition is administered as a plurality of doses (for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more doses). The endolysin, nucleic acid, vector/plasmid, host cell, bacteriophage or pharmacological composition is preferably administered at a frequency sufficient to maintain a continuous presence of the endolysin according to the first aspect of the invention in the vagina of the subject. Preferably, the dose and dosage frequency is sufficient to prevent occurrence or recurrence of a disease or condition associated with microbial cells in a subject (e.g., *Gardnrella*). Preferably, the dose and dosage frequency is sufficient to prevent occurrence or recurrence of growth impedance associated with microbial cells in a subject (e.g., *Gardnerella*).

[0124] In one embodiment, the uses and methods of the invention a host cell or pharmacological composition comprising a host cell is used to deliver the endolysin of the first aspect of the invention (preferably a host cell).

[0125] It will be appreciated that the medicaments described herein may be administered to a subject in combination with one or more additional therapeutic agents. For example, the medicaments described herein may be administered to a subject in combination with:

- (a) one or more conventional antibiotic treatments. Such antibiotics may include Clindamycin, Metronidazole or any other suitable antibiotics known by a skilled person in the art
- (b) one or more additional endolysins, or nucleic acid molecules, vectors, host cell or bacteriophage capable of expressing the same;

- (c) a compound or composition which adjusts the pH of the vagina, preferably to pH 4.0 to 6.0, more preferably to about pH 5.0. Such pH adjusting compounds may include phosphate, lactic acid (e.g. the natural acidification substance which *Lactobacilli* secrete to establish an acidic milieu) or other organic acids, e.g. carboxy-substituted polymers;
- (d) a therapy to neutralize the toxins released upon bacterial lysis of *G.vaginalis* cells within the vagina. Suitable neutralising therapies may include antibodies (see Babcock et al., 2006, *Infect. Immun.* 74:6339-6347) and toxinabsorbing agents such astolevamer (see Barker et al., 2006, *Aliment. Pharmacol. Ther.* 24:1525-1534)
- (e) a probiotic.

[0126] A further aspect of the invention provides the use of an endolysin having a cell lysing activity against *Gardnerella*, or a nucleic acid molecule, vector/plasmid, host cell or bacteriophage capable of expressing the same, for killing and/or inhibiting/preventing the growth of microbial cells *in vitro* and/or *ex vivo*, wherein the microbial cells are selected from the group consisting of *Gardnerella* cells and other bacterial cells susceptible to lysis with the endolysins of the invention. For example, the endolysins having said activity may be used to clean surfaces, such as those in hospitals, kitchens, etc, which may be susceptible to contamination with such bacterial cells. Preferably, the microbial cells comprise or consist of cells of *G.vaginalis sensu stricto*, *G. leopoldii*, *G. piotii*, *G. swidsinskii*, or other species of the genus *Gardnerella*.

[0127] A further aspect of the present invention provides a kit. Said kit comprises an endolysin as described herein and instructions of use, in particular for treating a disease or disorder, preferably BV. Said kit may be used for therapeutic or prophylactic purposes and may further comprise a compound or composition which adjusts the pH of the vagina to 4.0 – 6.0, preferably to 4.5-5.5, more preferably to about 5. However, the kit of the present invention may also be used for detecting the presence of microbial cells in a sample, the kit comprising a polypeptide having the cell lysing activity and/or cell binding specificity of an endolysin according to the invention or a nucleic acid molecule, vector/plasmid, host cell or bacteriophage capable of expressing the same, wherein the microbial cells are selected from the group consisting of *Gardnerella* cells and other bacterial cells susceptible to lysis with said endolysin.

[0128] Related aspects of the invention provide:

- (a) the use of a polypeptide having the cell wall binding activity and/or cell lysing activity of an endolysin according to the invention or a nucleic acid molecule, vector/plasmid, host cell or bacteriophage capable of expressing the same, in the preparation of a diagnostic agent for a disease or condition associated with microbial cells selected from the group consisting of *Gardnerella* cells and other bacterial cells susceptible to lysis with said endolysin;

(b) the use of a polypeptide having the cell wall binding activity and/or cell lysing activity of an endolysin according to the invention or a nucleic acid molecule, vector/plasmid, host cell or bacteriophage capable of expressing the same, for the diagnosis of a disease or condition associated with microbial cells selected from the group consisting of *Gardnerella* cells and other bacterial cells susceptible to lysis with said endolysin;

(c) the use of a polypeptide having the cell wall binding activity and/or cell lysing activity of an endolysin according to the invention or a nucleic acid molecule, vector/plasmid, host cell or prophage capable of expressing the same, for detecting the presence of microbial cells in a sample *in vitro* and/or *ex vivo*, wherein the microbial cells selected from the group consisting of *Gardnerella* cells and other bacterial cells susceptible to lysis with said endolysin; and

(d) an *in vitro* method for the diagnosis of a disease or condition which can be treated with the endolysin according to the present invention, the method comprising the steps of: (i) contacting a sample obtained from the subject with a polypeptide comprising or consisting of the C-terminal cell-wall binding region of the endolysin according to the present invention, and optionally the N-terminal catalytic domain of the endolysin according to the present invention, wherein the sample comprises microbial cells, and wherein the C-terminal cell-wall binding region of said endolysin is optionally labelled; (ii) testing whether the polypeptide binds to, and/or lyses, the microbial cells of the sample; and (iii) determining that a disease or condition can be treated with the endolysin according to the present invention if the polypeptide binds to, and/or lyses, the microbial cells. The microbial cells may be *Gardnerella* cells, preferably cells of *G. vaginalis sensu stricto*, *G. leopoldii*, *G. piovii*, *G. swidsinskii* or other species of the genus *Gardnerella*.

Thus, the invention provides an *in vitro* method for the diagnosis of a disease or condition which can be treated with the endolysin of the invention in a subject, the method comprising contacting a cell sample obtained from the subject with a polypeptide having the cell wall binding activity and/or cell lysing activity of an endolysin according to the invention, or a nucleic acid molecule, vector/plasmid, host cell or prophage capable of expressing the same, and determining whether the cells in the sample have been lysed thereby, wherein the microbial cells are selected from the group consisting of *Gardnerella* cells and other bacterial cells susceptible to lysis with said endolysin. Preferably, the microbial cells comprise or consist of cells of *G.vaginalis sensu stricto*, *G. leopoldii*, *G. piovii*, *G. swidsinskii* or other species of the genus *Gardnerella*. In such diagnostic uses and methods, lysis of the cells may be detected using methods well known in the art. For example, levels of ATP may be measured as an indicator of cell lysis.

[0129] In an alternative embodiment of the above defined uses and methods of the invention, the polypeptide comprises or consists of the cell wall binding domain of an endolysin

according to the invention. To permit detection, such a polypeptide may be fused to magnetic beads or used as a fusion protein comprising a suitable reporter or label (for example, green fluorescent protein or a color forming enzyme like HRP). Such diagnostic approaches are well established for endolysins from other systems, such as *Listeria* endolysins (for example, see *Loessner et al.*, 2002, *Mol Microbiol* 44, 335-49; *Kretzer et al.*, 2007, *Applied Environ. Microbiol.* 73:1992-2000).

[0130] Illustrative embodiments of the invention are described in the following non-limiting examples, with reference to the following figures.

EXAMPLES

[0131] Example 1 – Identification of natural endolysins in *Gardnerella* genomes

[0132] Endolysins are hydrolytic enzymes produced by bacteriophages in order to cleave the host's cell wall during the final stage of the lytic cycle. They have the capacity of targeting one of the five bonds in peptidoglycan (murein), the main component of bacterial cell walls, which allows the release of progeny virions from the lysed cell. To date, no bacteriophages lytic against *Gardnerella* have been isolated. Therefore it was also unknown whether endolysins from bacteriophage origins and having a lytic activity against *Gardnerella* could be successfully identified. The inventors investigated whether endolysins encoded by prophage sequences can be identified on various *Gardnerella* genomes. Prophages are bacteriophage genomes inserted and integrated into the circular bacterial DNA chromosome or existing as an extrachromosomal plasmid. This is a latent form of a phage, in which the viral genes are present in the bacterium without causing disruption of the bacterial cell. Identification of prophage sequences within bacterial genomes and plasmids can be performed using web-based tools which are known by the skilled person of the art. For example, such tools include but are not limited to PHASTER (Arndt *et al.*, 2016 *Nucleic Acids Res.* 44, W16–W21.), PROPHINDER (Lima-Mendez *et al.*, 2008 *Bioinformatics* 24, 863–865) or the like. The inventors succeeded to identify sequences on 14 *Gardnerella* genomes predicted to constitute intact or partial prophages. The sequences were found by identifying DNA regions that cluster genes predicted to be of viral origin. Viral gene clusters predicted to be only partial prophages as opposed to complete prophages were also included.

[0133] Then, the putative prophage sequences were annotated by blasting predicted coding sequences, to identify putative endolysins. Specifically, protein sequences homologous to enzymes capable of cleaving any of the key chemical bonds that constitute peptidoglycan

were searched. In particular, protein sequences homologous to N-actylmuramidases, N-actylmuramoyl-L-alanine amidases, L-alanoyl-D-glutamate endopeptidases, interpeptide bridge endopeptidases, or N-acetyl-beta-D-glucosaminidases were searched. On every individual prophage or partial prophage analyzed, the inventors discovered coding sequences for proteins homologous to 1,4-beta-N-acetylmuramidases and named them EL1 to EL14. The assignment of names to source genomes is shown in Table 1.

[Table 1]

Name of the putative endolysin	Name of the strain from which the putative endolysin has been identified
EL 1	Strain HMP9231
EL 2	Strain Gv18-4
EL 3	Strain Gv18-4
EL 4	Strain Gv5-1
EL 5	Strain JCP7276
EL 6	Strain 1400E
EL 7	Strain AMD
EL 8	Strain JCP7719
EL 9	Strain 0288E
EL 10	Strain G30-4
EL 11	Strain JCP8017A
EL 12	Strain 3549624
EL13	Strain Gv37_1
EL 14	Strain Gv37_2

Only one copy per prophage was found in each case, and no other coding sequences predicted to be enzymes capable of lysing the bacterial cell wall were found. The putative 1,4-beta-N-acetylmuramidases were aligned to understand homology and domain structure (see Fig. 1). As can be seen in Figure 1, the majority of endolysins, even from different prophages on different genomes has exactly 306 residues. The two exceptions are EL6 and EL9. EL6 is truncated at the C-terminus by a frameshift. EL9 ends at the exact same position as EL6, however in this case the whole contig ends. There are no identical pairs among the endolysins, even though they are highly homologous, as can be seen in Figure 2.

[0134] Example 2 – Determination of the domain structure of the natural *Gardnerella* prophage endolysins

[0135] The domain structure of the newly discovered endolysins were determined with InterPro (Mitchell *et al.*, 2019 Nucleic Acids Res. 47, D351–D360). Briefly, InterPro is a database of protein families, domains and functional sites in which identifiable features found in known proteins can be applied to new protein sequences in order to functionally characterize them. The contents of InterPro consist of diagnostic signatures and the proteins that they significantly match. The signatures consist of models, *e.g.* simple types, such as regular expressions or more complex ones, such as Hidden Markov models, which describe protein families, domains or sites. As can be seen in Figure 3, all endolysins with 306 residues have the same domain arrangement. The N-terminal domain of 196 residues is identified as the catalytic domain, due to its homology to Glycoside hydrolases, family 25. Said catalytic domain is followed by a linker region and two cell-binding domains homologous to the C-terminal domain of lysozyme Cpl-7, also called CW_7 domains (García *et al.*, 1990 Gene 86, 81–88; Lopez and García, 2004 FEMS Microbiol. Rev. 28, 553–580; Bustamante *et al.*, 2010 J. Biol. Chem. 285, 33184–33196, 2012 PLoS One 7, e46654). In the following examples, the above identified catalytic domain represents the “N-terminal catalytic domain” or “H-domain” where, *e.g.*, “H2” refers to the H-domain of the natural EL2. In the following examples, the “linker region” and the “C-terminal cell-wall binding region”, the latter comprising or consisting of one or more cell-wall binding domains or “B-domains”, represent together the “B-region” where, *e.g.*, B10 refers to the B-region of the natural EL10. Likewise, B11_N refers to the N-terminal cell-wall binding domain of natural EL11, B12_C refers to the C-terminal cell-wall binding domain of natural EL12 and so on.

[0136] Example 3 – Determination of the enzymatic activity of the natural *Gardnerella* prophage endolysins on *Gardnerella* cells

[0137] The inventors investigated the enzymatic activity of the newly discovered endolysins against *Gardnerella*. Whether or not the identified sequences homologous to 1,4-beta-N-acetylmuramidases were active could not be predicted *in silico*. As it is well-known in the art, bacteria can mutate their prophage sequences and the corresponding prophages might therefore lose their activity to propagate. Moreover, even if the newly discovered phage-encoded peptidoglycan hydrolases were indeed active proteins, it was still not demonstrated that said proteins were able to enzymatically degrade the specific peptidoglycan layer of *Gardnerella*. Indeed, *Gardnerella* is special in that it is a Gram-variable species: it does not form the outer membrane defining true Gram-negative species. Its cell wall is generally very thin and has only

10% or less content of peptidoglycan. Thus, a skilled person of the art would have thought that a peptidoglycan-degrading enzyme, such as endolysin proteins, could not efficiently lyse the bacterial cell walls of *Gardnerella*.

[0138] The 14 identified endolysins EL1 to EL14 were cloned with a His-tag, expressed in *E. coli* and purified via a single-step Ni-NTA column using the method described in Reference Example 1. The assignment of endolysins names to source genome is shown in Table 1. The *Gardnerella* strains used are shown in Table 2.

[Table 2]

Name	<i>Gardnerella</i> strains (new nomenclature following (Vanechoutte <i>et al.</i> , 2019))
Gv_1	UGent 09.07, strain of <i>G. vaginalis sensu stricto</i>
Gv_8	UGent 25.49, strain of <i>G. vaginalis sensu stricto</i>
Gv_9	ATCC 14018, type strain for <i>G. vaginalis sensu stricto</i>
Gv_10	UGent 06.41, type strain for <i>G. leopoldii</i>
Gv_11	UGent 09.48, type strain for <i>G. leopoldii</i>
Gv_17	UGent 18.01, type strain for <i>G. piovii</i>
Gv_23	GS 10234 (FC2), type strain for <i>G. swidsinskii</i>

To test the activity of the purified endolysins, the turbidity change of *Gardnerella* suspensions (see Table 2) was measured at 610-620nm using essentially the method described in Reference Example 2, where 95 μ l of bacterial suspension in Hardy Broth at the indicated pH was mixed with 5 μ l of endolysin solution in a photometric cuvette under aerobic conditions at room temperature. In turbidity reduction assays, a decrease in light scattering (*i.e.*, turbidity reduction) of a suspension of live cells can be used in a spectrophotometer to assay the activity of peptidoglycan hydrolases. The reduction in optical density over time (minutes) can be used to calculate a rate of hydrolysis. Results are compared to a “no-enzyme added, buffer only” control preparation treated identically for the same period of time. In this manner, a specific activity of the enzyme preparation can be reported as Δ OD/time/ μ l lysin protein. As can be seen in Figures 4A to 4C, the drop in turbidity was much more pronounced for the endolysin treated groups than for buffer, indicating enzymatic activity. Surprisingly, the inventors therefore discovered that the newly discovered endolysins EL1, EL2, EL3, EL4, EL5, EL7, EL10, EL11 and EL12 were active proteins having the capacity to lyse the *Gardnerella* cell walls. As explained above, due to

the low content of peptidoglycan in the cell wall, the fact that a peptidoglycan-degrading enzyme such as the identified endolysins could efficiently lyse the bacterial cell walls was an unexpected and surprising discovery.

[0139] Example 4 – Identification of the most active domains with artificial domain-swapped endolysins

[0140] Whether the different N-terminal enzymatic domains could have different lytic activities and whether the B-region (comprising the linker and the cell-wall binding domains) could mediate specificity to different strains was then assessed by the inventors. For that purpose, domain-swapped endolysins were artificially generated.

[0141] 4.1 - Endolysins constructs

[0142] To artificially generate the domains-swapped endolysins, the N-terminal 196 residues of a first natural endolysin, comprising the catalytic domain, were swapped as a block against the full C-terminal region of 110 residues of a second natural endolysin, comprising the linker region and two cell-wall binding domains. Domain-swapped proteins were prepared by performing the following methods. The original constructs EL1-14 were ordered from GeneWiz as synthetic genes with codon-optimization for *E. coli*. These constructs were cloned by GeneWiz into the pETM14_ccdB vector via restriction/ligation approach using the recognition sites for NcoI and NotI enzymes.

Table 3 below summarizes the primers used. For domain swapping of the selected 10 constructs, each H-domain together with the T7 promoter was amplified by a common forward primer (no 2) and a construct-specific reverse primer (no 3-12) using the PhusionFlash polymerase (Thermo, F-548L). Similarly, each B-region was amplified by a construct-specific internal primer (no 13-21) and a common reverse primer (no 1) including the T7 terminator. All primers contained extensions bearing the BsaI recognition site, making the outer ends compatible with the pETM14-derived vector backbone pETMdest. The overhang between the domains was designed to be of sequence “GGCT” within the two amino acids GL of the linker sequence. These 2 amino acids therefore represented the exact border between the domains for the purpose of this experiment.

Thus amplified and gel-purified domains (GeneJet Gel purification kit, Thermo, K0692) were then combined into 90 new expression constructs using the GoldenGate cloning strategy by BsaI restriction (BsaI-HFv2, NEB, R3733S)/ligation (T4 DNA Ligase, Thermo, EL0011) cycling reaction.

For transformation purposes, the NEB10beta E. coli strain was used (NEB, C3019) and plasmids were purified using the GeneGet Plasmid Miniprep Kit (Thermo, K0502).

[Table 3]

1	T7casette-16-rev	aacaggtctcaataacaatccggatatagttcctccttcagc
2	T7casette-01-for	aacaggtctcaacctccgcgaattaatacgaactcactatagg
3	EL_H1-rev	aacaggtctcaagccggcatttttgatgatgctcggg
4	EL_H2-rev	aacaggtctcaagccaacattttaataatgctcggataatcc
5	EL_H3-rev	aacaggtctcaagccggcggttttgataacgctcggg
6	EL_H4-rev	aacaggtctcaagcccacgttcttgatgatgctcgg
7	EL_H5-rev	aacaggtctcaagccggcggttttgatgatgctcgg
8	EL_H6-rev	aacaggtctcaagccggcatttetaataatgctcggata
9	EL_H7-rev	aacaggtctcaagccggcggttttaataatgctcggataatc
10	EL_H10-rev	aacaggtctcaagccggcggttttgatcacgctcgg
11	EL_H11-rev	aacaggtctcaagccggcggttttgataacgctcggataatc
12	EL_H12-rev	aacaggtctcaagccggcattcttgatcacgctcgg
13	EL_B6-for	aacaggtctcaggcttaaacggctgcaaaaatggcgg
14	EL_B7-for	aacaggtctcaggcttaaacggctgcaaaaacgggtgg
15	EL_B10-for	aacaggtctcaggcttaaacggctataaaaacggcggc
16	EL_B11-for	aacaggtctcaggcttaaatggttacaagaatggcggcag
17	EL_B12-for	aacaggtctcaggcttaaatggctaccagaacggcgg
18	EL_B1-for	aacaggtctcaggcttaaacggctgcaagaatggtgg
19	EL_B2-for	aacaggtctcaggcttaaatggtgcaagaacggcgg
20	EL_B3-for	aacaggtctcaggcttaaatggctaccagaatggcggc
21	EL_B4-for	aacaggtctcaggcttaaatggctgcaaaaacgggtggc
23	T7term-STOP-for	aacaggtctcatgacgccattaacctgatgttctggg

For ease of reference, the domain combination of the artificial endolysins is expressed with a H-code for the N-terminal catalytic domain (thereafter called the H-domain) and a B-code for the part comprising the C-terminal cell-wall binding region and the linker region (thereafter called the B-region). By way of example, H2B10 refers to a domain-swapped endolysin with the N-terminal domain from the natural endolysin EL2, and the linker region and C-terminal cell-wall binding region from the natural endolysin EL10. In other words, H2B10 refers to a domain-swapped endolysin consisting of the 196 N-terminal residues of the natural endolysin EL2 (SEQ ID NO: 2) and the 110 C-terminal residues of the natural endolysin EL10. In this example, the B-region B10 corresponding to the 110 C-terminal residues of the natural endolysin EL10, comprises from the C-terminal to the N-terminal order, a C-terminal cell-wall binding domain “B10_C” (SEQ ID NO: 29), a N-terminal cell-wall binding domain “B10_N” (SEQ ID NO: 28)

and a linker region “L10” (NAGLNGYKNGGS). The nomenclature and the corresponding amino acid sequences are displayed in details in Table 7.

Therefore, according to above nomenclature, a natural endolysin, e.g. EL3, can be defined either as H3B3 or H3-L3-(B3_N)(B3_C) interchangeably. Likewise, a recombinant endolysin, e.g. H2B10, can also be defined as H2-L10-(B10_N)(B10_C) interchangeably.

A skilled person of the art would understand that the elements “Lx”, “(Bx_N)” and “(Bx_C)” might also be swapped independently in other embodiments. The nomenclature is further displayed in Table 7, below.

[0143] 4.2 - Optimization of assay parameters

[0144] The dependence of activity on three potentially critical parameters was analyzed, i.e. pH, anaerobic/micro-aerophilic/aerobic conditions, absence/presence of imidazole. The three criteria to assess have been selected for the following reasons.

- pH: The killing activity of the endolysins of the invention has been successfully demonstrated with experiments conducted at pH values around 7. However, the pH in a healthy vagina is about 3.5 while in a BV vagina the pH is up to about 5.5 and even higher. Therefore, the pH-dependence of the endolysins activity has been investigated.

- Oxygen: In literature, *Gardnerella* is described as anaerobic or micro-aerophilic. Therefore, it has been investigated whether more untreated cells survived under anaerobic, micro-aerophilic or aerobic conditions for the incubation period of the experiment (usually 5 hours).

- Imidazole: According to the method described in Reference Example 1, the endolysins of the invention are purified via a one-step Ni-NTA column, where the buffer used to elute the endolysins from the Ni-NTA matrix contained Imidazole. Therefore, in the absence of a further step of dialyzing the sample, the obtained eluate solutions contain 250mM Imidazole. In that respect, the effect of imidazole on *Gardnerella* has been investigated.

First, the sensitivity of *G. vaginalis* Gv_9 survival to incubation in medium with or without imidazole at different pH values was assessed (see Fig. 6). 5×10^7 CFU/ml cells were incubated under the conditions indicated below the graph for 5 hours at 37°C under anaerobic conditions. Then, the surviving CFU/ml was determined by quantitative plating. As depicted in Fig. 6, at pH 6.0, a median of 1×10^7 and 1×10^6 cells survive the incubation without and with imidazole, respectively. At pH 7.0, only medians of 2×10^6 and 3×10^4 cells survive without and with imidazole, respectively. In the untreated control at pH 5.0, 1×10^7 cells survive the procedure, while the median survival of Imidazole treated at pH 7 is 3×10^4 , i.e. 3 logs below the former. Therefore, the survival of *G. vaginalis* Gv_9 is highly dependent on the absence of imidazole, especially at pH >6.0, and of a low pH.

Second, the sensitivity of *G. vaginalis* Gv_9 to treatment with the recombinant endolysin H10B1 against control containing imidazole at different pH values was assessed (see Fig. 7). 5×10^7 CFU/ml cells were incubated under the conditions indicated below the graph for 5 hours at 37°C under anaerobic conditions. Then, the surviving CFU/ml was determined by quantitative plating. The columns labeled imidazole control depict the same data as in Fig. 5. As depicted in Fig. 7, the endolysin is highly active down to pH 5.0, and even the relative reduction vs. control is much more pronounced at this low pH, with a reduction in viable CFU of 2.5 logs. While at pH 7.0 there was less than 1 log₁₀ difference in survival between H10B1-treated and untreated cells, the difference was 2 log₁₀ units at pH 5.0. The survival of cells not treated with H10B1 did not increase at pH values lower than 6.0 in presence of imidazole. Therefore, the activity of the endolysin H10B1 is highly pH dependent. When similar experiments were conducted under aerobic conditions, the survival of control cells was reduced by several log₁₀ units compared to anaerobic conditions (data not shown).

Therefore, it has been concluded that the optimized parameters to conduct the experiments with the endolysins of the invention were under anaerobic conditions, at pH 5.0, and with a step of removing imidazole from the endolysin eluates.

[0145] 4.3 - Expression levels

[0146] Table 4 depicts an overview of the concentrations of all endolysin constructs. Each construct that had a concentration above 0.2mg/ml after the removal of imidazole were adjusted to a concentration of 0.2mg/ml by dilution. Constructs with a lower concentration were left as is and tested for their activity. Natural endolysin EL6 (not shown in Table 4) had a concentration below 0.2mg/ml. H4, H11 and H12 appear to confer low solubility and expression levels, as most constructs fell under the threshold of 0.2mg/ml. Also for H1 several constructs had a low concentration.

[Table 4]

Overview of expression levels (quantitative)

	B1	B2	B3	B4	B5	B7	B10	B11	B12
H1	0.2				0.2	0.2	0.2	0.2	
H2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
H3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
H4							0.2	0.2	
H5	0.2	0.2	0.2	0.2		0.2	0.2	0.2	0.2
H7		0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
H10	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
H11			0.2				0.2		0.2
H12									

[0147] 4.4 – Quantitative assessment of the lysis of the four main species of *Gardnerella* by endolysin action in suspension under optimized conditions

[0148] The lysis activity on the four main species of *Gardnerella* of 91 constructs (natural and domain-swapped endolysins) was quantitatively assessed using the method described in Reference Example 2. Briefly, 90ul 5e7 CFU/ml of the indicated strain were incubated for 5hours at pH 5.0 under anaerobic conditions with 10ul endolysin (concentration adjusted to 0.2mg/ml where possible, see Table 4).

The results are shown in Figures 8A to 8D together with Tables 5A to 5C. In figures 8A to 8D, the logarithmic Y axis depicts the count of surviving cells. The dotted line indicates the limit of detection (LOD) given by plating of 2ul of the reaction mix (500 CFU/ml). Each combination of the natural 10 H-domains and the natural 9 B-regions was assessed, including the natural endolysins (H1B1, H2B2, H3B3, etc.), plus H6B6. No other constructs with the B-domain B6 were tested, as B6 made all H-domains fused to it inactive, as determined by OD measurement (data not shown). The activity of each construct was measured on each of the 4 main *Gardnerella* species *G. vaginalis sensu stricto*, *G. leopoldii*, *G. piovii*, and *G. swidsinkii*. Table 5 summarizes the resulting log10 reduction of CFU, organized by H-domain and B-region. All conditions have been measured in triplicate. The survival after 5 hours incubation at pH 5.0 under anaerobic conditions with endolysins vs. buffer was measured by quantitative plating. The values indicate the log10 of the ratio of surviving CFU for treated vs. untreated cells. The average of the triplicate measurements is used. In tables 5A and 5B, high negative log10 values, e.g. -6.7, -5.5, -4.8 etc. are associated with high enzymatic activity, while log10 values closer to zero or even positive log10 values are associated with low or no enzymatic activity. To provide an example, if the average CFU of the 3 control treated measurements on Gv_9 were 1.0×10^7 CFU/ml, and the average of the 3 samples treated with H2B10 was 2.5×10^3 CFU/ml, then the log10 value of the CFU reduction of Gv_9 by H2B10 would be $\log_{10}(2.5 \times 10^3 / 10^7) = -3.7$. Inversely, a reduction value of -3.7 means a $10^{3.7}$ -fold (=5012-fold) reduction of viable CFU in treated sample vs. untreated control.- In case of an inactive endolysin, e.g. H4B3 on Gv_9, the Gv_9 CFU after treatment would be equal to the CFU measured in the control treated sample and the ratio of the two CFU values would be one. Therefore, the reduction value of H4B3 on Gv_9 is $\log_{10}(1) = 0.0$.

Table 5B below depicts the same data as Table 5A, but displayed as averages of the log10 activities of each construct across the four *Gardnerella* strains. At the right and bottom, average values of each natural H-domain across all natural B-regions (except B6), and each natural B-region (except B6) across all natural H-domains, respectively, are shown along with the activity rank of the respective natural H-domain and natural B-region.

[Table 5B]

	B1	B2	B3	B4	B5	B6	B7	B10	B11	B12	Avg	Rank
H1	-1.9	-0.6	-0.9	-1.1	-1.7		-1.8	-2.8	-1.9	-1.0	-1.5	7
H2	-1.8	-2.6	-3.0	-2.5	-2.5		-2.9	-4.3	-4.2	-4.1	-3.1	1
H3	-2.4	-2.5	-3.0	-2.2	-1.7		-1.3	-2.0	-2.1	-1.9	-2.1	5
H4	0.3	0.3	0.1	-0.8	0.3		-0.4	-3.1	-3.2	-1.4	-0.9	9
H5	-1.9	-1.7	-3.1	-2.9	0.1		-2.3	-3.0	-2.5	-2.5	-2.2	4
H6	-0.7	-1.1	-0.7	-0.8	-0.8	0.0	-1.0	-0.9	-1.5	-0.7	-0.8	10
H7	-1.6	-2.4	-3.4	-2.8	-2.0		-2.0	-3.3	-3.1	-3.0	-2.6	2
H10	-1.9	-2.0	-2.9	-2.4	-1.7		-1.7	-3.3	-2.9	-3.3	-2.4	3
H11	-1.3	-0.3	-2.6	-1.8	-1.8		-0.9	-2.6	-1.5	-2.7	-1.7	6
H12	-0.6	-0.9	-1.1	-0.8	-1.0		-1.1	-1.2	-2.1	-0.9	-1.1	8
Avg	-1.4	-1.4	-2.1	-1.8	-1.3		-1.5	-2.7	-2.5	-2.1		
Rank	7	8	4	5	9		6	1	2	3		

Table 5C depicts the activity ranks of all endolysins, based on the data of Table 5B.

[Table 5C]

	B1	B2	B3	B4	B5	B6	B7	B10	B11	B12
H1	44	83	72	63	53		50	21	43	67
H2	49	25	12	26	29		17	1	2	3
H3	33	27	13	35	52		61	39	36	46
H4	91	90	88	76	89		84	9	8	59
H5	42	55	11	18	87		34	14	30	28
H6	80	66	79	78	77	86	68	71	58	81
H7	56	32	4	20	38		40	5	10	15
H10	45	41	16	31	54		51	6	19	7
H11	60	85	24	47	48		70	23	57	22
H12	82	74	64	75	69		65	62	37	73

Table 5D depicts the average log₁₀ lysis of each *Gardnerella* strain used. The averages were calculated of the log₁₀ activities across all constructs tested.

[Table 5D]

Log₁₀ average activity across all constructs by strain

Gv_9 (<i>G. vaginalis</i>)	-1.5
Gv_11 (<i>G. leopoldii</i>)	-1.5
Gv_17 (<i>G. piovii</i>)	-1.1
Gv_23 (<i>G. swidsinskii</i>)	-3.4

Tables 5A to 5C show that the activity of the endolysins was highly specific dependent on the H-domain/B-region combination and the bacterial strain it was tested on. Each construct was assayed against the four *Gardnerella* strains (see Table 5A). On average, the most active H-domain is H2, with an average reduction of 3.1 log₁₀ units of CFU across all B-regions (except B6), followed by H7, H10 and H5 (see Table 5B). Of the B-regions, B10 is the most active, with an average CFU reduction of 2.7 log₁₀ units, followed by B11, B12, and B3.

Surprisingly and unexpectedly, the inventor discovered that several recombinant endolysins have a stronger activity than any natural endolysin (H1B1 to H12B12), especially when viewed across all 4 *Gardnerella* strains tested (see Figures 8A to 8D). Particularly H2B10, H2B11, and H2B12 have activity ranks 1, 2, and 3, respectively, and each is more active than any natural endolysin (see Table 5C). H7B3 has rank 4 overall (see Table 5C) and is also more active than any other natural endolysin included in the experiment. In fact, the only natural endolysin ranking within the 10 most active is H10B10 (rank 6), the next most active natural endolysin being H3B3 (rank 13). In summary, recombinant endolysins according to the present disclosure might exhibit significantly higher activity than the natural endolysins.

While not being restricted to a particular theory, the unexpected increase of killing activity against *Gardnerella* observed by domain-swapping the endolysins according to the invention can be explained as follows. Natural endolysins on prophages undergo a Darwinian evolution process, where the propagation of the whole prophage is being optimized. However, the probability of mutations that lead to higher propagation of the respective prophage by simultaneously improving the catalytic activity of the endolysin and at the same time broadening its host range across species within only *Gardnerella* is very low. In the contrary, some *Gardnerella* prophages must have evolved the N-terminal catalytic domain of the endolysin to highest activity, and some other prophages must have optimized the C-terminal region of the endolysin for broadest activity across *Gardnerella* species. Therefore, by combining an highly

evolved N-terminal catalytic domain of one of the endolysins of the invention with an highly evolved C-terminal region of another endolysin of the invention encoded by a different genome from a different prophage, recombinant endolysins with higher optimized killing activity against *Gardnerella* species than the natural endolysins of the invention can be achieved. This is for example achieved by the recombinant endolysins of the invention H2B10, H2B11, H2B12, and H7B3, which all have a higher killing activity than the natural endolysins EL2 or any other natural endolysins, and that across all *Gardnerella* species (see Figures 8A to 8D and Tables 5A).

Moreover, most constructs are much more active on Gv_23 (*G. swidsinskii*) than on the other three strains tested (see Table 5A). The average activity across all constructs on each *Gardnerella* strain (see Table 5D) confirms that Gv_23 is the most susceptible to endolysins, followed by Gv_9 and Gv_11, while Gv_17 (*G. piovii*) is the least susceptible. This order of susceptibility is mostly the case across endolysin constructs. While Gv_23 is the most susceptible strain, for many constructs by several log10 units, sometimes Gv_17 is more susceptible than Gv_9 or Gv_11 (e.g. for H2B10, the most active endolysin overall). Without being bound by a particular theory, the susceptibility difference can be explained by either a structural deficits like a weaker/thinner/more accessible cell wall of Gv_23, or a stronger enzymatic activity on Gv_23 of the endolysins tested.

Furthermore, it can be concluded that the concentration of the endolysins in solution is critical for their activity in the assay. The constructs with low concentration as depicted in Table 4 generally also have a low activity in the activity assay – particularly the ones with the H-domains H4, H11 and H12 (which confer low solubility across B-regions). There are few surprises, like H12B11, which had a very low expression level but comparably high activity.

[0149] 4.5 - Activity pattern analysis

[0150] The sequences of the natural H-domains were aligned and compared to relate to the activity patterns, as depicted in the dendrogram of Fig. 9. It was expected that the most active H-domains are also most closely related to each other. However, surprisingly, the most active N-terminal domain, H2, is most homolog to H6, which is the least active. The next-most active H-domains, H7 and H10, are also rather distantly related to each other and to H2. The fourth-most active H-domain, H5, is most closely related to H7. Also the combinations with the B-regions which make the recombinant endolysins most active do not lead to a predictable pattern. H2 is most active in combination with B10, B11 and B12. However the second most active H-domain, H7, is most active in combination with B3, as is the case for its closest homolog, H5.

Also the B-regions were aligned to reconcile homologies to the activity pattern, as depicted in the dendrogram of Fig. 10. The most active B-regions as of the analysis in Tables 5A to 5C are B10, B11, B12, followed by B3, which all have average CFU reduction values above 2 log10 units. In contrast to the pattern seen for H-domains, these 4 most active B-regions are the 4 closest homologs within the group of tested B-regions. Interestingly, the B5 and B7 regions are identical (see Fig. 10). The best overall results were obtained for H2B10, H2B11 and H2B12 as can be seen in Figures 8A to 8D.

As explained in Example 2, each natural B-region comprises two B-domains, namely a N-terminal cell-wall domain and a C-terminal cell-wall domain. The sequence of each natural B-domain within the B-region were also aligned and compared, as depicted in Figures 11 and 12. The boundaries of the B-domains can be identified both by analyzing the sequence with Interpro (Mitchell *et al.*, 2019 Nucleic Acids Res. 47, D351–D360)) and by aligning the two repetitive motifs within each B-region. The C-terminus of all B-domains is a conserved sequence (VNE LL or VNKLL), homologous to which can be found also at the C-terminus of the CW_7 motifs (VNE LL or VNEIL) of the protein Cpl-7, thereby defining the boundaries of the two B-domains in each B-region. As an exception, B6 has only one truncated B-domain, which is likely to be the reason for the complete inactivity of EL6.

Concluding, the specific combination of H-domain and B-region has been shown to be critical and each of the H/B combinations leading to endolysins with higher killing activities compared to the natural endolysins was a surprising and non-predictable discovery.

[0151] Example 5 – Activity assay against beneficial *Lactobacilli*

[0152] The healthy vagina is populated mainly by 3 species of *Lactobacilli*: *L. crispatus*, *L. gasseri* and *L. jensenii*. These maintain an acidic pH of 3.5-4.5, by producing lactic acid, and a protective oxidative milieu, by producing H₂O₂. Recovery from BV is associated with a repopulation of the vagina with these *Lactobacilli*, and a pharmaceutical against BV should advantageously not interfere with this process. Antibiotics obviously do, which is why there is still a strong medical need for improved methods and compositions to treat *Gardnerella* infections and BV. After having successfully demonstrated the high activity of the endolysins of the invention on *Gardnerella*, the inventors investigated whether those endolysins can lyse strains of the 3 most frequent *Lactobacilli* species in the healthy vagina. The experiment has been performed using the method described in Reference Example 2 at pH 5.0, under anaerobic conditions. As depicted in Fig. 13, the recombinant endolysins tested do not exhibit any killing activity against the three species of beneficial *Lactobacilli* used, namely *L. crispatus*, *L. gasseri*

and *L. jensenii*. The endolysins of the invention, although exhibiting a high killing activity against *Gardnerella*, are ineffective against the most frequent beneficial *Lactobacilli*. These results therefore confirm the genus-selective activity of the endolysins of the invention and their drug candidate status as an innovative pharmaceutical against BV. In that respect, treating BV with the endolysins of the invention is far advantageous to the currently available treatments, such as the treatments with the antibiotics Metronidazole and Clindamycin.

[0153] Example 6 – Activity assays of standard of care antibiotics Metronidazole and Clindamycin on the growth in suspension of the *Gardnerella* strains

[0154] One of the main deficiencies in the treatment of BV is the high rate of recurrence in many women, which leads to repeated administration of antibiotics and concomitant destabilization of the microbiome and other side effects. The minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) on *Gardnerella* cells of the strains also used for the endolysin activity assays were then measured using the method described in Reference Example 6 and 7. Briefly, the measurement protocol had to be strongly adapted from the international standard, which is not suited for MIC and MBC measurements on *Gardnerella*. The main parameters to change were the growth medium (*Gardnerella* does not grow in Mueller-Hinton Broth usually used for MIC measurements), the anaerobic conditions, the time of incubation, and in the first round of experiments also the starting concentration of bacteria. The starting concentration was changed from the standard of 5×10^5 CFU/ml to 2.5×10^7 CFU/ml, mainly because also in the vagina of a BV patient, the cells are very concentrated, and the effect of the antibiotic should be measured at cell densities more comparable to ones used for the endolysin activity assays. The effect of Metronidazole (obtained from Gatt-Koller) and Clindamycin (obtained from Ratiopharm) on the growth in suspension of the *Gardnerella* strains was assessed. Essentially, *Gardnerella* suspensions at 2.5×10^7 CFU/ml were incubated with the concentration of antibiotics as indicated and incubated for 48h at 37°C under anaerobic conditions. MIC was defined as the minimal concentration of antibiotic at which no growth was detectable after 48h by OD measurement. OD(610) was measured at the beginning and the end of the experiment. At the end of the experiment, 2ul of each reaction mix was spotted on agar to determine the MBC. Table 6A summarizes the results of the experiment described in Fig. 14. Resistance (R) defined as ≥ 32 µg/ml for Metronidazole and >8 mg/ml for Clindamycin. Sensitivity (S) is defined as ≤ 8 µg/ml for Metronidazole and ≤ 2 µg/ml for Clindamycin, according to international standards.

[Table 6A]

	Metronidazole		Clindamycin	
	MIC	MBC	MIC	MBC
<i>G. vaginalis</i> (Gv_9)	128 ug/ml - R	>128 ug/ml	16 ug/ml - R	128 ug/ml
<i>G. leopoldii</i> (Gv_11)	>128 ug/ml - R	>128 ug/ml	16 ug/ml - R	32 ug/ml
<i>G. piovii</i> (Gv_17)	64 ug/ml - R	>128 ug/ml	16 ug/ml - R	64 ug/ml
<i>G. swidsinskii</i> (Gv_23)	>128 ug/ml - R	>128 ug/ml	16 ug/ml - R	>128 ug/ml

[Table 6B]

	Metronidazole [µg/ml]		Clindamycin [µg/ml]	
	MIC	MBC	MIC	MBC
<i>G. vaginalis</i> (Gv_9)	8	16 (R)	0.25	0.5
<i>G. leopoldii</i> (Gv_11)	128 (R)	>128 (R)	0.5	1
<i>G. piovii</i> (GV_17)	16	64 (R)	0.25	1
<i>G. swidsinskii</i> (Gv_23)	32 (R)	>128 (R)	0.25	0.25

According to the results displayed in Fig. 14, all *Gardnerella* strains have a low susceptibility both to Metronidazole and Clindamycin. The conditions under which MIC and MBC were measured are more rigorous than the standard. For example usually, the MBC_{90} is measured, *i.e.* the antibiotic concentration killing 90% of cells within a defined time, while MBC has been defined in the present application as the minimal concentration fully eradicating a suspension of 2.5×10^7 CFU/ml. Nevertheless, these conditions are more comparable to what is found in the vagina of a BV patient. The high MIC and MBC values measured under these conditions could explain the high recurrence rates of BV. The assayed endolysins in contrast are bactericidal by definition, since they lead to complete disintegration of the bacterial cell. These results therefore sustain that the endolysins of the invention are superior to antibiotics in the treatment of BV.

A second round of MIC and MBC experiments was performed, where some experimental parameters were changed (i) the starting number of cells of 1×10^5 - 1×10^6 was now in accordance

with the CLSI (Clinical and Laboratory Standards Institute) standards, (ii) Clindamycin hydrochloride powder (Sigma Aldrich, cat. no. C5269) was used (iii), NYC-III broth instead of Hardy broth, and (iv) 96-well plate instead of 384-well plates. As displayed in FIG. 15 and summarized in Table 6B, all *Gardnerella* strains still have a very low MIC to Metronidazole (8-128 µg/ml), whereas Clindamycin hydrochloride - in contrast to Clindamycin presented in FIG. 14 and Table 6A - was now inhibitory and bactericidal at low concentration ($\text{MIC} \leq 1 \mu\text{g/ml}$).

Example 7 – Activity assays of a representative (H2B10) of domain swapped endolysins on the growth in suspension of different *Gardnerella* strains. For the analysis of MIC and MBC with the endolysin H2B10 cells suspensions of 1×10^5 - 1×10^6 were used. H2B10 showed a MIC in the low µg/ml range (0.5-4 µg/ml) indicating that *Gardnerella* cells are highly sensitivity towards endolysins (FIG. 16, Table 7). The conditions under which MBC was measured are more rigorous than the standard. For example usually, the MBC_{90} is measured, *i.e.* the antimicrobial concentration killing 90% of cells within a defined time, while MBC has been defined in the present application as the dose that reduced the starting cell number by at least 99.5%. H2B10, as a representative of the herein claimed endolysins, showed a vastly superior MIC and MBC over the standard of care antibiotic Metronidazole, which is ineffective on many *Gardnerella* strains due to resistance formation. Clindamycin, however, gave inconsistent results. According to the international standards all four *Gardnerella* strains were supposed to be resistant ($\text{MIC} > 8 \mu\text{g/ml}$) to Clindamycin, which was obtained from Ratiopharm (FIG. 14), whereas Clindamycin hydrochloride (Sigma Aldrich) was much more effective with bactericidal effects already at concentrations $\leq 1 \mu\text{g/ml}$ (FIG. 16). In general, it is known, that antibiotics only insufficiently eradicate the *Gardnerella* biofilm, a hallmark of BV, which is one suspected reason for the reported very high recurrence rate of BV. Despite leaving residual viable biofilm, antibiotics wipe parts of the beneficial organisms of the vaginal microbiome which then opens an ecological niche for other pathogens, e.g. fungi. Thus, endolysin-based treatment that selectively eradicates bacterial cells of the genus *Gardnerella* and presumably eradicates the biofilm without harming the beneficial *Lactobacilli* is supposed to be superior to standard antibiotics therapy of BV.

Table 7

	H2B10 [µg/ml]	
	MIC	MBC
<i>G. vaginalis</i> (Gv_9)	1	2
<i>G. leopoldii</i> (Gv_11)	4	16
<i>G. swidsinskii</i> (GV_23)	0.5	1

[0155] Reference Example 1 - Cloning, expression and purification of endolysins

Materials:

- 96-well Multiscreen HTS Durapore 96-well Filterplatten, PS (Labshop cat. no. 44.MSGVS22)
- PD MiniTrap desalting columns with Sephadex G-25 (GE Lifescience, cat. no. 28918007)
- Slide-A-Lyzer™ MINI Dialysis Device, 10K MWCO, 2 mL (Thermo Scientific, cat. no. 88404)
- Fastbreak reagent (Promega, cat. no. V8571)
- Lysis Buffer: 50 mM Phosphate pH 6, 150 mM NaCl, 20 mM Imidazole, 1 mM TCEP, 1x FastBreak, Benzonase.
- Wash Buffer I: 50 mM Phosphate pH 6, 150 mM NaCl, 20 mM Imidazole, 1 mM TCEP(1,5ml)
- Wash Buffer II: 50 mM Phosphate pH 6, 150 mM NaCl, 40 mM Imidazole, 1 mM TCEP(1,5ml)
- Elution Buffer: 50 mM Phosphate pH 6, 150 mM NaCl, 250 mM Imidazole, 1 mM TCEP(1,1ml).

Method:

Expression constructs were transformed into *E. coli* strain B121(DE3) and selected using appropriate antibiotics. Cells from 2 ml of culture (TB + Lactose, 25 °C, O/N) were resuspended in 1.5 ml Lysis Buffer and lysed by FastBreak reagent (Promega). The intracellular soluble fraction was isolated by centrifugation at 15000 g, 30 min, 4°C. The soluble protein fraction was loaded onto 100 µL of Nickel affinity matrix, washed with 15 column volumes (CV) of Wash Buffers I and II each, and eluted in 10 CV elution buffer. Then, the eluate buffer might be exchanged to 20mM phosphate pH 6.0, 150mM NaCl, to remove imidazole, using desalting

columns. After elution (or buffer exchange as appropriate), the concentration of the purified protein was adjusted to 0.2mg/ml, then the solutions were sterile filtered using a 96-well filter plate.

[0156] Reference Example 2 - Activity assays in bacterial suspensions

Materials:

1. Hardy Broth, autoclaved 20min at 121°C:

- 12.0g of Pancreatic Digest of Casein (SigmaAldrich, cat. no. 70172-100G)
- 10.0g of Proteose Peptone (SigmaAldrich, cat. no. 82450-100G)
- 5.0g of Peptic Digest of Animal Tissue (SigmaAldrich, cat. no. 70174-100G)
- 5.0g of Sodium Chloride(CarlRoth, cat. no. 3957.1)
- 3.0g of Beef Extract (SigmaAldrich, cat. no. B4888-50G)
- 3.0g of Yeast Extract (SigmaAldrich, cat. no. Y1625-250G)
- 1.0g of Soluble Starch (Sigma Aldrich, cat. no. S9765-250G)
- deionized H₂O to 1 liter (produced in the PhagoMed Lab with Millipore RiOs Essential 16)

2. Hardy Broth Agar, autoclaved 20min at 121°C: Same as Hardy Broth, but with 15g Agar Bacteriological (OXOID Cat. # LP0011)

3. Hardy Broth Top Agar, autoclaved 20min at 121°C: Same as Hardy Broth, but with 7g Agar Bacteriological (OXOID Cat. # LP0011)

4. NYC-III medium, pH 5.0, autoclaved 20min at 121°C, after which horse serum is added (NYC-III-HS-5.0)

- 12g HEPES (Sigma Life Science, cat. no. H4034-100G)
- 7.5g Proteose Peptone No. 3 (BD, cat. no. 211693)
- 1.9g Yeast Extract (Sigma Aldrich, cat. no. Y1625-250G)
- 2.5g Sodium Chloride (Sigma Aldrich, cat. no. S9888-1kg-M)
- 2.5g Glucose (MW 180.16 g/mol) (Sigma Aldrich, cat. no. G6152-1KG)
- deionized water to 450ml total volume
- 50ml Horse Serum (HS), heat inactivated 100 ml (Thermo Fisher Scientific, cat. no. 26050070), added after autoclaving

5. General materials:

- BD Chocolate agar plates for Gardnerella (BD, cat. no. 254060)
- BD Schaedler/ 5% sheep blood plates for Lactobacilli (BD, cat. no. 254042)
- Isovitalex (BD, cat. no. 211876)
- Hardy broth + Isovitalex (see above), adjusted to pH as indicated
- Hardy agar + Isovitalex (see above)
- Hardy top agar + Isovitalex (see above)
- 96-U-well plate (Sigma Aldrich, cat. no. M2311-100EA)
- 96 flat-bottom plate with lid (Labshop, cat. no. 44.781662)
- Greiner CELLSTAR® 384 well plates (Sigma-Aldrich, cat. no. M1937-32EA)
- Anaerogen sachets (Sigma-Aldrich, cat. no. 68061-10SACHETS-F)
- Anaerobe indicator test (Sigma-Aldrich, cat. no. 59886-1PAK-F)
- Anaerobic jar (Sigma-Aldrich, cat. no. 28029-1EA-F) or a plastic lunch box sealable with a rubber gasket, purchased at a local home appliances store

6. Bacterial strains:

Gardnerella strains:

- Gv_1: UGent 09.07
- Gv_8: UGent 25.49
- Gv_9: ATCC 14018
- Gv_10: UGent 06.41
- Gv_11: UGent 09.48
- Gv_17: UGent 18.01
- Gv_23: GS 10234 (FC2)

Lactobacilli strains:

- *L. jensenii* PB2003-013-T2-2
- *L. gasseri* 020566
- *L. crispatus* LAB117

Method:

Gardnerella cells were recovered from cryo stock by plating on Chocolate Agar plates (Beckton Dickinson) and incubating for 48h at 37°C under anaerobic conditions. For Lactobacilli, BD

Schaedler/5% sheep blood agar plates were used instead. Colonies were scraped from the plate, resuspended in Hardy Broth or NYC-III-HS-5.0 at the pH as indicated, and the suspension adjusted to OD (610 or 620nm as indicated) 0.1. It has to be noted that two Tecan Microplate readers, having respectively a 610nm or 620nm filter, have been used interchangeably in the experiments. Although it doesn't make any difference for the experiments, the exact wavelength used is specified in each example. If not stated otherwise, 90µl cell suspension was mixed with 10µl endolysin solution, for the different species/endolysin combinations, in 384-well plates. OD(610-620nm as indicated) was measured at the beginning of the reaction and at the end, either as two measurement points or as a continuous kinetic in a Tecan F200 Microplate reader. The reactions were incubated for 5 hours (or otherwise the time indicated) at 37°C under anaerobic, micro-aerophilic or aerobic conditions as indicated. Anaerobic conditions intend that oxygen was fully depleted from the container in which the bacteria are incubated (Sigma-Aldrich anaerobic jar or sealable lunch box) with an anaerobic sachet, and the lack of oxygen was confirmed with an anaerobic indicator inside the container. Where micro-aerophilic conditions are indicated, the candle-in-a-jar method was used (tea candle lit in an appropriate sealable container, which reduces oxygen levels until the flame dies out). Then each well was diluted in 5 steps (10^{-1} to 10^{-5}) using 96-U-well bottom plates, and 2µl of each dilution of each reaction mix are plated on BD Chocolate agar plates or BD Schaedler/5% sheep blood agar plates for *Gardnerella* and *Lactobacilli*, respectively, for detecting and quantifying surviving CFU. Detection plates were incubated at 37°C for 48 hours under anaerobic conditions.

[0157] Reference Example 6 and 7– MIC and MBC measurements

Materials:

General materials:

- Metronidazole (Gatt-Koller, Metronidazolium mikronisiert, 10g, 606293914)
- Clindamycin (Ratiopharm, 300mg/2ml ampulles 5x)
- Clindamycin hydrochloride (Sigma Aldrich, 10 mg, cat. no. C5269)
- Endolysin H2B10 [530µg/ml] in MES buffer (50 mM MES, 100 mM NaCl, 8 mM MgSO₄, pH=5.5)
- BD Chocolate agar plates for Gardnerella (BD, cat. no. 254060)
- BD Schaedler/ 5% sheep blood plates for Lactobacilli (BD, cat. no. 254042)
- Isovitalax (BD, cat. no. 211876)
- Hardy broth + Isovitalax (see above), adjusted to pH as indicated

- NYC-III + HS broth, pH 5.5 NYC-III-HS Agar plates: NYC-III + HS medium as described above, but with 1.5% Agar added prior to autoclaving
- Hardy agar + Isovitalex (see above)
- Hardy top agar + Isovitalex (see above)
- 96-U-well plate (Sigma Aldrich, cat. no. M2311-100EA)
- 96 flat-bottom plate with lid (Labshop, cat. no. 44.781662)
- Greiner CELLSTAR® 384 well plates (Sigma-Aldrich, cat. no. M1937-32EA)
- Anaerogen sachets (Sigma-Aldrich, cat. no. 68061-10SACHETS-F)
- Anaerobe indicator test (Sigma-Aldrich, cat. no. 59886-1PAK-F)
- Anaerobic jar (Sigma-Aldrich, cat. no. 28029-1EA-F) or a plastic lunch box sealable with a rubber gasket, purchased at a local home appliances store

Method:

Bacteria were plated from cryo stock on BD Choc Agar plates (*Gardnerella*) and incubated at 37°C for 48h under anaerobic conditions. Colonies were scraped from the plate, resuspended in Hardy Broth or NYC-III-HS-pH 5.0, and the suspension adjusted to OD (610 or 620nm as indicated) 0.05. It has to be noted that two Tecan Microplate readers, having respectively a 610nm or 620nm filter, have been used interchangeably in the experiments. Although it doesn't make any difference for the experiments, the exact wavelength used is specified in each example. Antibiotics were prepared as 20x stocks for each of the required final concentrations. 95µl of cell suspension was mixed with 5µl antibiotics dilution in a 384-well plate. OD (610-620 as indicated) at the start of the reaction was measured, then the plate was incubated at 37°C for 48h under anaerobic conditions. After that, the OD (610-620 as indicated) was measured again for MIC determination, where MIC was defined as the lowest concentration of antibiotic where the OD (610-620 as indicated) was not above the level measured at the beginning of the experiment. After measuring OD, 2µl of each well were spotted on a NYC-III+HS Agar plate. The plates were then incubated for further 48h at 37°C under anaerobic conditions. After incubation, cell growth on each spot was evaluated, and the MBC defined as the lowest concentration of antibiotics where no bacteria grew on the plate. The experiments were conducted in triplicate for each condition.

In the second round of MIC and MBC experiments with antibiotics the *Gardnerella* cell suspension was adjusted to the McFarland standard 0.5 (approximately OD (610) 0.07) and then diluted 1:75 according to the CLSI (Clinical and Laboratory Standards Institute) standards.

Antibiotics were prepared according to the CLSI standards and 50µl of cell suspension was mixed in a 96-well plate with 50µl antibiotics. Otherwise the MIC and MBC was determined as described above.

For the MIC and MBC determination of the domain swapped endolysin H2B10 50µl of *Gardnerella* cell suspension was mixed in a 96-well plate with 50µl of H2B10 containing solution, which were serially diluted 1:1. OD₆₁₀ at the start of the reaction was measured, then the plate was incubated at 37°C for 48h under anaerobic conditions. After that, the OD(610) was measured again for MIC determination, where MIC was defined as the lowest concentration of H2B10 where the OD was not or only slightly above the level measured at the beginning of the experiment.

[Table 7]

Natural endolysin	Structure from N-terminal to C-terminal*			
EL1	H1	L1	B1 N	B1 C
	SEQ ID NO: 1	NAGLNGCKNGGS	SEQ ID NO: 15	SEQ ID NO: 16
EL2	H2	L2	B2 N	B2 C
	SEQ ID NO: 2	NVGLNGCKNGGS	SEQ ID NO: 17	SEQ ID NO: 18
EL3	H3	L3	B3 N	B3 C
	SEQ ID NO: 3	NAGLNGYQNGGS	SEQ ID NO: 19	SEQ ID NO: 20
EL4	H4	L4	B4 N	B4 C
	SEQ ID NO: 4	NVGLNGCKNGGS	SEQ ID NO: 21	SEQ ID NO: 22
EL5	H5	L5	B5 N	B5 C
	SEQ ID NO: 5	NAGLNGCKNGGS	SEQ ID NO: 23	SEQ ID NO: 24
EL6	H6	L6	B6 N	
	SEQ ID NO: 6	NAGLNGCKNGGS	SEQ ID NO: 25	
EL7	H7	L7	B7 N	B7 C
	SEQ ID NO: 7	NAGLNGCKNGGS	SEQ ID NO: 26	SEQ ID NO: 27
EL8	SEQ ID NO: 8			
EL9	SEQ ID NO: 9			
EL10	H10	L10	B10 N	B10 C
	SEQ ID NO: 10	NAGLNGYKNGGS	SEQ ID NO: 28	SEQ ID NO: 29
EL11	H11	L11	B11 N	B11 C
	SEQ ID NO: 11	KAGLNGYKNGGS	SEQ ID NO: 30	SEQ ID NO: 31
EL12	H12	L12	B12 N	B12 C
	SEQ ID NO: 12	NAGLNGYQNGGS	SEQ ID NO: 32	SEQ ID NO: 33
EL13	SEQ ID NO: 13			
EL14	SEQ ID NO: 14			

*1st row = Name according to the nomenclature of the present application, if appropriate; 2nd row = the corresponding native amino acid sequence

SEQUENCES LISTING

SEQ ID NO: 1

>H1

>196 aa

MSKKGIDVSEWQGDIDFNAVKASGVEFVIIIRAGYGIGCKDKWFEQNYRKAKTAGLDVGAYWYSYANGSFE
AAEEAQSLMNMLSGKSFEYPVYFDLEEKSQLNRGRAFCDSLITSFCKLEACGYAGFYTSLSTANNLVS
AHVRNRYALWIAQWNTHCNYQGSYGLWQYSSSGSVPGVAGRVDMDYAYVDYPSIIK

SEQ ID NO: 2

>H2

>196 aa

MSKKGIDVSEWQGDIDFNAVKASGVEFVIIIRAGYGIGCKDKWFEQNYRKAKTCGLDVGAYWYSYANGSFE
AAEEAQSCVNMLSGKSFEYPVYFDLEEKSQLNRGRAFCDSLITGFCNKLESCGYAGFYTSLSTANNLVS
AHVRNRYALWIAQWNTHCSYQGSYGLWQYSSSGSVPGVAGRVDMDYAYVDYPSIIK

SEQ ID NO: 3

>H3

>196aa

MSKKGIDVSVWQGDIDFNSVKASGVEFVIIIRAGYGIGHKDKWFEENYRKAKTAGLDVGSYWYSYASSAGE
ASEEAQSCVNILSGKSFEYPIYFDLEEKSQLNRGRDFCDLITSFCKLEACGYAGFYTSLSVNNLVS
SHVRDRYALWIAQWNTHCSYQGSYGLWQYSSSGSVNGIAGRVDMDYAYVDYPSVIK

SEQ ID NO: 4

>H4

>196aa

MSKKGIDVSEWQGDIDFNAVKASGVEFVIIIRAGYGIGCKDKWFEQNYRKAKTCGLDVGAYWYSYANGSFE
AAEEAQSCVNMLSGKSFEYPVYFDLEEKSQLNRGRAFCDSLITSFCKLETYGYAGFYTSLSVNNLVS
AHVRDRYALWIAQWNTHCSYQGSYGLWQYSSSGSVPGVAGRVDMDYAYVDYPSIIK

SEQ ID NO: 5

>H5

>196 aa

MSKKGIDVSEWQGDIDFNAVKASGVEFVIIIRAGYGIGCKDKWFEQNYRKAKTAGLDVGAYWYSYANSSSE
AAEEAQSCANMLSGKSFEYPVYFDLEEKSQLNRGRAFCDSLITGFCCKLEACGYAGFYTSLSTANNLVS
AHVRNRYALWIAQWNTHCSYQGSYGLWQYSSSGSVPGVAGRVDMDYAYKDYPSIIK

SEQ ID NO: 6

>H6

>196 aa

MSKKGIDVSVWQGDIDFNAVKASGVEFVIIIRAGYGIGCKDKWFEQNYRKAKTCGLDVGAYWYSYANGSFE
AAEEAQSCVNMLSGKSFEYPVYFDLEEKSQLNRGRAFCDSLITSFCKLESCGYAGFYTSLSTANNLVS
AHVRNRYALWIAQWNTHCDYQGSYGLWQYSSSGSVPGVAGRVDMDYAYKNYPSIIK

SEQ ID NO: 7

>H7

>196aa

MSKKGIDVSEWQGDIDFNAVKASGVEFVIIIRAGYGIGCKDKWFEQNYRKAKTAGLDVGAYWYSYANSASE
AAEEAQSCANMLSGKSFEYPVYFDLEEKSQLNRGRAFCDSLITSFCKLETYGYAGFYTSLSTANNLVS
SHVRNRYALWIAQWNTHCSYQGSYGLWQYSSSGSVPGVAGRVDMDYAYKDYPSIIK

SEQ ID NO: 8

>EL8

>306 aa

MSKKGIDVSEWQGDIDFNAVKASGVEFVIIIRAGYGIGCKDKWFEQNYRKAKTAGLDVGAYWYSYANSSSE
AAEEAQSCVNMLSGKSFEYPPVYFDLEEKSQLNRGRAFCDSLITSFCSKLETYGYAGFYTSLSTANNLVS
SHVRNRYALWIAQWNTHCSYQGSYGLWQYSSNGSVPGVAGRVDMDYAYVDYPSIIKNAGLNGYKNGGSYT
APQTSSIDDVAREVINGAWGNGNERKQRLTQAGYDYTSVQNKVNKLLGVKACRKSVDLAREVIRGTWGN
GNERKNRLTQAGYDYDTVQKRVNELL

SEQ ID NO: 9

>EL9

>251 aa

MSKKGIDVSEWQGDIDFNAVKASGVEFVIIIRAGYGIGCKDKWFEQNYRKAKTCGLDVGAYWYSYANSNGFE
AAEEAQSCVNMLSGKSFEYPPVYFDLEEKSQLNRGRVFCDSLITSFCNKLEACGYAGFYTSLSTANNLVS
SHVRNRYALWIAQWNTHCDYQGSYGLWQYSSSGSVPGVAGRVDMDYAYVDYPSIIKNAGLNGCKNGGSDQ
AARTSSIDEVAREVINGAWGNGSTRKQRLTSAGYDYASVAK

SEQ ID NO: 10

>H10

>196aa

MSKRGIDVSVWQGDIDFNAVKASGVEFVIIIRAGYGIGHKDKWFEENYRKAKTVGLDVGAYWYSYASSAGE
ASEEAQSCVNILSGKSFEYPPVYFDLEEKSQLNRGRDFCDLITSFCNKLEACGYAGFYTSLSVANNLVS
SHVRDRYALWIAQWNTHCSYQGSYGLWQYSSSGSVNGIAGRVDMDYAYVDYPSVIK

SEQ ID NO: 11

>H11

>196aa

MSKRGIDVSVWQGDIDFNAVKASGVEFVIIIRAGYGIGHKDKWFEQNYRKAKTTGLDVGAYWYSYASSAGE
AAEEAQSCVNILSGKSFEYPPVYFDLEEKSQLNRGRDFCDLITSFCNKLETYGYAGFYTSLSVANNLVS
SHVRDRYALWIAQWNTHCDYQGSYGLWQYSSSGSVNGIAGRVDMDYTYVDYPSVIK

SEQ ID NO: 12

>H12

>196 aa

MSKKGIDVSVWQGDIDFNAVKASGVEFVIIIRAGYGIGHKDKWFEENYRKAKTAGLDVGSYWYSYASSAGE
VALEAQSCVNILSGKSFEYPPVYFDLEEKSQLNRGRDFCDLITSFCNKLEACGYAGFYTSLSVANNLVS
SHVRDRYALWIAQWNTHCSYQGSYGLWQYSSSGSVNGIAGRVDMDYAYVDYPSVIK

SEQ ID NO: 13

>EL13

>306 aa

MSKKGIDVSVWQGDIDFNAVKASGVEFVIIIRAGYGIECKDKWFEQNYRKAKTAGLDVGAYWYSYANSNGFE
AAEEAQSCVNMLSGKSFEYPPVYFDLEEKSQLNRGRAFCDSLITSFCNKLESCGYAGFYTSLSTANNLVP
AHVRNRYALWIAQWNTHCDYQGSYGLWQYSSSGSVPGVAGRVDMDYAYVDYPSIIKNAGLNGYKNGESHQ
ATRTTSIDEVAREVINGAWGNGNERKQRLTQAGYDYASVQNKVNELLGVKACRKSVDLAREVIRGTWGN
GNERKNRLTSAGYDYDTVQKRVNELL

SEQ ID NO: 14

>EL14

>306 aa

MSKKGIDVSVWQGDIDFNAVKASGVEFVIIIRAGYGIGCKDKWFEQNYRKAKTCGLDVGAYWYSYANSNGFE
AAEEAQSCVNMLSGKSFEYPPVYFDLEEKSQLNRGRAFCDSLITSFCNKLEACGYAGFYTSLSTANNLVS
AHVRNRYALWIAQWNTHCSYQGSYGLWQYSSSGSVPGVAGRVDMDYAYVDYPSIIKNAGLNGYKNGESHQ
ATRTTSIDEVAREVINGAWGNGNERKQRLTSAGYDYASVQNKVNELLGVKACRKSVDLAREVIRGAWGN
GSTRKQRLTSAGYDYDTVQKRVNELL

SEQ ID NO: 15

>B1_N

>49 aa

DQAARTSSIDEVAREVINGAWGNGSTRKQRLTSAGYDYASVQNKVNELL

SEQ ID NO: 16

>B1_C

>49 aa

GVKACRKSVDLAREVIRGAWGNGSTRKQRLAQAGYDYDTVQKRVNELL

SEQ ID NO: 17

>B2_N

>49 aa

DQAARTSSIDEVAREVINGAWGNGNERKQRLTSAGYDYASVQNKVNELL

SEQ ID NO: 18

>B2_C

>49 aa

GVKACRKSVDLAREVIRGTWNGSTRKQRLTQAGYDYDTVQKRVNELL

SEQ ID NO: 19

>B3_N

>49 aa

YTAPQTSSIDEVAREVINGDWGNGNDRKNRLISAGYDYASVQNKVNELL

SEQ ID NO: 20

>B3_C

>49 aa

GVKAYRKSVDLAREVIRGTWNGSMRKHRLTQAGYDYDAVQKRVNELL

SEQ ID NO: 21

>B4_N

>49 aa

DQATRTSSIDEVAREVINGAWGNGNERKQRLTSAGYDYASVQNKVNKLL

SEQ ID NO: 22

>B4_C

>49 aa

GVKAYRKSVDLAREVIRGTWNGNERKQRLAQAGYDYDTVQKRVNELL

SEQ ID NO: 23

>B5_N

>49 aa

DQAARTSSIDEVAREVINGAWGNGNERKQRLTQAGYDYTSVQNKVNKLL

SEQ ID NO: 24

>B5_C

>49 aa

GVKACRKSVDLAREVIRGTWNGNERKNRLTQAGYDYDTVQKRVNELL

SEQ ID NO: 25

>B6_N

>43 aa

NQAARTSSIDDVAREVINGAWGNGNERKQRLTQAGYDYASVAK

SEQ ID NO: 26

>B7_N

>49 aa

DQAARTSSIDEVAREVINGAWGNGNERKQRLTQAGYDYTSVQNKNKLL

SEQ ID NO: 27

>B7_C

>49 aa

GVKACRKSVDLAREVIRGTWNGNERKNRLTQAGYDYDTVQKRVNELL

SEQ ID NO: 28

>B10_N

>49 aa

YTAPQTSSIDEVAREVINGDWGNGNERKQRLTSAGYDYASVQNKNVNEEL

SEQ ID NO: 29

>B10_C

>49 aa

GVKAYRKSVDLAREVIRGTWNGSTRKQRLTQAGYDYNVQKRVNELL

SEQ ID NO: 30

>B11_N

>49 aa

YTAPQTSSIDEVAREVINGDWGNGNERKNRLTSAGYDYTSVQNKNVNEEL

SEQ ID NO: 31

>B11_C

>49 aa

GVKAYRKSVDLAREVIRGTWNGSTRKQRLTQAGYDYDAVQKRVNELL

SEQ ID NO: 32

>B12_N

>49 aa

YTAPQTSSIDEVAREVINGDWNGIERKNRLTSAGYDYTSVQNKNVNEEL

SEQ ID NO: 33

>B12_C

>49 aa

GVKAYRKSVDLAREVIRGTWNGKTRKQRLTQAGYDYNVQKRVNELL

Claims

1. A recombinant endolysin comprising or consisting of
 - (i) a N-terminal catalytic domain, or a functional variant thereof,
 - (ii) a C-terminal cell-wall binding region, or a functional variant thereof, wherein the C-terminal cell-wall binding region comprises or consists of one or more cell-wall binding domains, and
 - (iii) a linker region between the N-terminal catalytic domain and the C-terminal cell-wall binding region,wherein the N-terminal catalytic domain is from a first natural endolysin, the linker region and the C-terminal cell-wall binding region are from a second natural endolysin, and wherein the first and the second natural endolysins are encoded by different genomes from different prophages, and wherein said recombinant endolysin has a genus-selective killing activity against *Gardnerella*.
2. The recombinant endolysin of claim 1 wherein the N-terminal catalytic domain is a polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 1 to 5, 7, or 10 to 12, or any variant thereof having at least 80% identity with the amino acid sequence of any one of SEQ ID NOs: 1 to 5, 7, or 10 to 12, whereby said polypeptide is functional, wherein the function comprises the ability to lyse the cell wall of *Gardnerella*.
3. The recombinant endolysin of any one of the precedent claims wherein the C-terminal cell-wall binding region comprises or consists of one, two or three cell-wall binding domains.
4. The recombinant endolysin of claim 3 wherein the one, two or three cell-wall binding domains are independently selected from the group consisting of the polypeptides comprising or consisting of the amino acid sequence of SEQ ID NOs: 15 to 24 and 26 to 33, respectively, and any variants thereof having at least 80% identity with the amino acid sequence of SEQ ID NOs: 15 to 24 and 26 to 33, respectively, whereby said polypeptides are functional, wherein the function comprises the ability to bind to the cell wall of *Gardnerella*.

5. The recombinant endolysin of any one of the preceding claims wherein the C-terminal cell-wall binding region comprises or consists of a first cell-wall binding domain and a second cell-wall binding domain, wherein said first cell-wall binding domain is selected from the group consisting of SEQ ID NOs: 15, 17, 19, 21, 23, 26, 28, 30 and 32 and said second cell-wall binding domain is selected from the group consisting of SEQ ID NOs: 16, 18, 20, 22, 24, 27, 29, 31 and 33.
6. The recombinant endolysin of claim 5 wherein said first cell-wall binding domain is N-terminally of said second cell-wall binding domain.
7. The recombinant endolysin of any one of the precedent claims wherein the linker region is a polypeptide comprising or consisting of the amino acid sequence:
 - (i) (XXX)_n, wherein each X can be independently G, A or S, preferably wherein the amino acid sequence (XXX)_n is (GGS)_n, wherein n corresponds to the number of repetitions of the sequence XXX, preferably wherein n is 2, 3, 4, 5 or 6; or
 - (ii) X₁X₂GLNGX₃X₄NGGS, wherein X₁ is N or K, X₂ is A or V, X₃ is Y or C and X₄ is K or Q.
8. The recombinant endolysin of any one of the precedent claims wherein said endolysin has a killing activity against *Gardnerella vaginalis sensu stricto*, *Gardnerella leopoldii*, *Gardnerella piovani* and/or *Gardnerella swidsinskii*, or any other species in the genus *Gardnerella*.
9. The recombinant endolysin of any one of the precedent claims wherein said endolysin has no killing activity against *Lactobacilli*, preferably wherein said endolysin has no killing activity against *Lactobacilli crispatus*, *Lactobacilli gasseri*, and/or *Lactobacilli jensenii*.
10. A polynucleotide which encodes the recombinant endolysin of any one of claims 1 to 9.
11. A pharmaceutical composition comprising the recombinant endolysin of any one of claims 1 to 9 or the polynucleotide of claim 8 and further comprising a pharmaceutically acceptable carrier and/or diluent.

12. A recombinant endolysin as defined in any one of claims 1 to 9, a polynucleotide as defined in claim 10 or a pharmaceutical composition as defined in claim 11 for use in treating a disease or disorder.
13. The recombinant endolysin for use according to claim 12, the polynucleotide for use according to claim 12 or the pharmaceutical composition for use according to claim 12 wherein said disease or disorder is a bacterial infection.
14. The recombinant endolysin for use according to claim 13, the polynucleotide for use according to claim 13 or the pharmaceutical composition for use according to claim 13 wherein said bacterial infection is bacterial vaginosis.
15. The recombinant endolysin for use according to claim 14, the polynucleotide for use according to claim 14 or the pharmaceutical composition for use according to claim 14 wherein said bacterial vaginosis is caused by *Gardnerella vaginalis sensu stricto*, *Gardnerella leopoldii*, *Gardnerella piovai* and/or *Gardnerella swidsinskii*.
16. The recombinant endolysin for use according to any one of claims 13 to 15, the polynucleotide for use according to any one of claims 13 to 15 or the pharmaceutical composition for use according to any one of claims 13 to 15 wherein said recombinant endolysin, polynucleotide or pharmaceutical composition is to be administered locally, preferably wherein said recombinant endolysin, polynucleotide or pharmaceutical composition is to be administered locally into the vagina of a female subject and/or into or on the glans penis, prepuce or urethral entry of a male subject.
17. The recombinant endolysin for use according to any one of claims 13 to 15, the polynucleotide for use according to any one of claims 13 to 15 or the pharmaceutical composition for use according to any one of claims 13 to 15 wherein said recombinant endolysin, polynucleotide or pharmaceutical composition is to be administered into the vagina of a female subject and/or into or on the glans penis, prepuce or urethral entry of a male subject.
18. The recombinant endolysin for use according to any one of claims 13 to 17, the polynucleotide for use according to any one of claims 13 to 17 or the pharmaceutical

composition for use according to any one of claims 13 to 17 wherein said recombinant endolysin, polynucleotide or pharmaceutical composition is to be co-administered with a compound or composition which adjusts the pH of the vagina to 4.0 – 6.0.

19. A plasmid comprising the polynucleotide of claim 10.
20. A bacterial host cell comprising the plasmid of claim 19, preferably wherein the bacterial host cell is an *E. coli* cell.
21. An *in vitro* method for the diagnosis of a disease or condition which can be treated with the endolysin according to any one of claims 1 to 9, the method comprising the steps of:
 - (i) contacting a sample obtained from the subject with a polypeptide comprising or consisting of the C-terminal cell-wall binding region of the endolysin according to any one of claims 1 to 9, and optionally the N-terminal catalytic domain of the endolysin according to any one of claims 1 to 9, wherein the sample comprises microbial cells, and wherein the C-terminal cell-wall binding region of said endolysin is optionally labelled;
 - (ii) testing whether the polypeptide binds to, and/or lyses, the microbial cells of the sample; and
 - (iii) determining that a disease or condition can be treated with the endolysin according to any one of claims 1 to 9 if the polypeptide binds to, and/or lyses, the microbial cells.